"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,CA,A1,CA 3137850 A1,174-350-403-845-80X,2022-05-05,2022,CA 3137850 A,2021-11-05,US 202063110231 P,2020-11-05,METHODS AND SYSTEMS FOR SIMULATING AND PREDICTING DYNAMICAL SYSTEMS WITH VECTOR-SYMBOLIC REPRESENTATIONS,"The present invention relates to methods and systems for simulating and predicting dynamical systems with vector symbolic representations of continuous spaces. More specifically, the present invention specifies methods for simulating and predicting such dynamics through the definition of temporal fractional binding, collection, and decoding subsystems that collectively function to both create vector symbolic representations of multi-object trajectories, and decode these representations to simulate or predict the future states of these trajectories. Systems composed of one or more of these temporal fractional binding, collection, and decoding subsystems are combined to simulate or predict the behavior of at least one dynamical system that involves the motion of at least one object.",APPLIED BRAIN RES INC,VOELKER AARON;;ELIASMITH CHRISTOPHER DAVID;;BLOUW PETER;;DUMONT NICOLE SANDRA-YAFFE;;STEWART TERRANCE,,https://lens.org/174-350-403-845-80X,Patent Application,no,0,0,2,2,0,G06N3/08;;G06N3/049;;G06N3/042;;G06N3/044;;G06F30/27;;G06F30/27;;G06N3/049;;G06F30/17,G06F17/10;;G06N20/00,,0,0,,,,PENDING
2,US,A1,US 2022/0138382 A1,014-550-496-647-240,2022-05-05,2022,US 202117520379 A,2021-11-05,US 202117520379 A;;US 202063110231 P,2020-11-05,METHODS AND SYSTEMS FOR SIMULATING AND PREDICTING DYNAMICAL SYSTEMS WITH VECTOR-SYMBOLIC REPRESENTATIONS,"The present invention relates to methods and systems for simulating and predicting dynamical systems with vector symbolic representations of continuous spaces. More specifically, the present invention specifies methods for simulating and predicting such dynamics through the definition of temporal fractional binding, collection, and decoding subsystems that collectively function to both create vector symbolic representations of multi-object trajectories, and decode these representations to simulate or predict the future states of these trajectories. Systems composed of one or more of these temporal fractional binding, collection, and decoding subsystems are combined to simulate or predict the behavior of at least one dynamical system that involves the motion of at least one object.",APPLIED BRAIN RES INC,VOELKER AARON RUSSELL;;ELIASMITH CHRISTOPHER DAVID;;BLOUW PETER;;STEWART TERRANCE;;DUMONT NICOLE SANDRA-YAFFE,,https://lens.org/014-550-496-647-240,Patent Application,yes,0,1,2,2,0,G06N3/08;;G06N3/049;;G06N3/042;;G06N3/044;;G06F30/27;;G06F30/27;;G06N3/049;;G06F30/17,G06F30/27;;G06F30/17;;G06N3/04,,0,0,,,,PENDING
3,ES,T3,ES 2650804 T3,144-618-115-192-409,2018-01-22,2018,ES 09734929 T,2009-04-24,US 4815208 P;;US 4850008 P;;US 2009/0002536 W,2008-04-25,Anticuerpos contra FcRn y uso de los mismos,"Un anticuerpo aislado o un fragmento de unión a antígeno del mismo que comprende una secuencia de dominio variable de inmunoglobulina de cadena pesada (HC) y una secuencia de dominio variable de inmunoglobulina de cadena ligera (LC), en donde las secuencias de dominio variable de inmunoglobulina de cadena pesada y cadena ligera forman un sitio de unión a antígeno que se une a un FcRn humano tanto a pH 6,0 como a pH 7,5 con una constante de disociación (KD) de no más de 10 nM, y en donde el anticuerpo o un fragmento de unión a antígeno del mismo comprende seis CDRs que, en combinación, son al menos 95% idénticas a: (a) CDRs de HC 1-3 de M0161-B04, a saber SEQ ID NOS: 174-176 respectivamente, y (b) CDRs de LC 1-3 de M0161-B04, a saber SEQ ID NOS: 171-173 respectivamente.",DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT;;WOOD CLIVE;;BITONTI ALAN;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/144-618-115-192-409,Granted Patent,no,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;G01N33/68,,0,0,,,,ACTIVE
4,JP,A,JP 2019162105 A,078-221-927-063-488,2019-09-26,2019,JP 2019046955 A,2019-03-14,US 4815208 P;;US 4850008 P,2008-04-25,ANTIBODY AGAINST FCRN AND USE THEREOF,"To provide antibodies against FcRn, pharmaceutical compositions comprising the same, and use thereof.SOLUTION: An isolated antibody comprises a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, where the heavy chain and light chain immunoglobulin variable domain sequences form an antigen binding site that binds to human FcRn.SELECTED DRAWING: Figure 36",DYAX CORP;;BIOGEN HEMOPHILIA INC,CHRISTOPHER TENHOOR;;ARUMUGAM MURUGANANDAM;;LADNER ROBERT CHARLES;;CLIVE WOOD;;ALAN J BITONTI;;JAMES STATTEL;;KEVIN MCDONNELL;;LIU LIMIN;;JENNIFER DUMONT;;AARON SATO,,https://lens.org/078-221-927-063-488,Patent Application,no,2,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C12N15/13;;A61K39/39;;A61K39/395;;A61K45/00;;A61K47/68;;A61K49/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P5/16;;A61P7/00;;A61P7/04;;A61P9/00;;A61P13/12;;A61P17/00;;A61P19/02;;A61P21/00;;A61P21/04;;A61P25/00;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;C07K16/28;;C07K16/46;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/62;;G01N33/53,,0,0,,,,PENDING
5,EP,A1,EP 3670538 A1,096-797-741-797-939,2020-06-24,2020,EP 19210915 A,2009-04-24,US 4815208 P;;US 4850008 P;;EP 17195757 A;;EP 09734929 A;;US 2009/0002536 W,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF,"This disclosure provides,  inter alia,  proteins that bind to FcRn,  e.g.,  immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;BIOVERATIV THERAPEUTICS INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,BIOVERATIV THERAPEUTICS INC. (2021-10-06);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021-10-06),https://lens.org/096-797-741-797-939,Patent Application,yes,53,0,69,71,190,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61K39/395;;A61P37/00,,99,85,046-418-619-195-508;;080-206-847-305-383;;001-885-424-057-412;;031-817-252-763-890;;053-519-394-609-859;;030-199-397-665-51X;;004-906-446-973-883;;085-172-902-751-941;;011-483-806-642-730;;011-052-821-413-843;;000-202-910-533-267;;038-256-556-798-926;;054-019-549-143-703;;120-214-453-828-332;;025-426-299-802-257;;000-782-271-097-14X;;038-256-556-798-926;;004-906-446-973-883;;174-783-722-981-415;;049-134-753-209-354;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;033-797-614-829-293;;048-188-266-680-461;;050-465-090-140-473;;017-328-464-709-648;;023-676-781-371-861;;073-188-128-290-445;;009-817-530-258-10X;;100-049-580-404-573;;072-378-691-723-546;;005-119-615-003-591;;034-331-211-704-877;;025-395-146-381-464;;011-962-497-035-168;;116-821-682-892-530;;047-865-259-862-039;;006-528-517-743-856;;020-010-536-497-604;;119-013-590-539-100;;029-694-380-116-357;;049-928-993-608-092;;063-830-914-171-200;;123-176-483-512-245;;101-386-538-214-614;;092-023-577-402-127;;039-508-259-975-855;;002-664-741-683-318;;021-641-900-032-887;;021-641-900-032-887;;103-477-074-900-777;;051-940-176-386-905;;029-667-686-534-996;;007-551-089-881-647;;002-237-818-610-496;;007-364-858-655-289;;056-942-841-068-650;;007-178-177-990-322;;136-081-470-295-245;;048-685-340-891-994;;053-356-650-362-67X;;000-025-810-068-033;;035-181-446-169-624;;074-644-618-813-918;;077-977-371-680-838;;078-111-943-124-60X;;003-452-898-892-099;;004-863-960-524-08X;;063-137-267-247-313;;095-153-055-114-800;;085-812-916-734-336;;011-247-307-412-311;;087-617-084-673-049;;000-092-434-393-958;;039-262-924-716-099;;152-520-430-306-466;;038-308-787-457-936;;035-803-984-874-05X;;008-778-244-900-75X;;049-415-660-020-852;;005-737-717-273-670;;056-726-428-144-81X;;070-640-740-750-988;;011-539-181-910-335,10.4049/jimmunol.178.8.5390;;17404325;;10.1016/1074-7613(94)90082-5;;7889418;;17296831;;10.1001/archneur.64.2.169;;12592318;;10.1067/mai.2003.142;;pmc7100438;;17516710;;10.2165/00063030-200721030-00002;;15682382;;10.1002/jps.20297;;pmc1280965;;10.1172/jci24394;;16284651;;10.1172/jci200418838;;15124024;;pmc398424;;10.1172/jci18838;;10.1038/nri2155;;17703228;;7578107;;10.1021/bi00045a005;;9048207;;10.1007/bf02786322;;8643606;;pmc39277;;10.1073/pnas.93.11.5512;;12646614;;10.4049/jimmunol.170.7.3528;;8871627;;10.4049/jimmunol.157.8.3317;;10.1046/j.1365-2567.1997.00326.x;;pmc1363983;;9370926;;10.1152/ajprenal.0164.2001;;11788451;;8643606;;pmc39277;;10.1073/pnas.93.11.5512;;pmc1280965;;10.1172/jci24394;;16284651;;10.1038/nbt1291-1373;;1369462;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;2531466;;10.1126/science.2531466;;2315699;;10.1126/science.2315699;;10.1146/annurev.immunol.6.1.381;;3289571;;10.1146/annurev.iy.06.040188.002121;;10.1016/0959-440x(95)80064-6;;8574707;;10.1126/science.3929380;;3929380;;10373423;;10.1074/jbc.274.26.18218;;9661810;;10.1016/s1380-2933(98)00007-4;;1385989;;10.3233/hab-1992-3204;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;10.1038/352624a0;;1907718;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;7522328;;10.1073/pnas.91.19.9022;;pmc44739;;11101809;;10.1038/82407;;10.1016/s0076-6879(00)28409-7;;11075357;;10.1016/s0022-1759(99)00149-0;;10648932;;10.1038/79494;;10973222;;10.1016/s0167-5699(00)01667-4;;10916139;;10656818;;10.1006/jmbi.1999.3444;;11160276;;10.4049/jimmunol.166.4.2228;;2456341;;1759716;;10.1021/ac00020a025;;1404388;;10.1016/0022-2836(92)90223-7;;7779254;;10.1016/0167-5699(95)80166-9;;10.1016/0022-2836(92)90224-8;;1404389;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;10.1016/s0022-1759(00)00290-8;;11292488;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;10.1016/s0065-2776(08)60486-1;;1502974;;9700502;;10.1111/j.1600-065x.1998.tb01188.x;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;9815943;;8790200;;10.1006/gyno.1996.4577;;9103398;;6847134;;10.1002/ana.410130302;;10.1002/ana.1032;;11456302;;6685237;;10.1212/wnl.33.11.1444;;6371137;;10.1016/0008-8749(89)90228-1;;2784075;;10.1136/gut.43.1.29;;pmc1727189;;9771402;;10.1080/00365520310000654;;12678333;;19188571;;10.1212/01.wnl.0000341766.59028.9d;;pmc2677532;;10.1126/science.162.3853.526;;5706935;;4563443;;10.1146/annurev.bi.41.070172.004211;;10328771;;10.1006/abio.1999.4063;;10606671;;10.1093/nar/28.2.e3;;pmc102535;;10976071;;10.1126/science.289.5485.1760;;6655236;;10.1016/0022-1759(83)90311-3;;10.1016/0076-6879(86)21078-2;;3724495;;4360349;;10.1021/bi00702a028;;10.1042/bj0890114;;14097352;;pmc1202279;;4185494;;10.1042/bj1130299;;pmc1184636;;10.1016/0019-2791(71)90484-8;;5170158;;7079720;;10.1038/scientificamerican0582-78;;6547405;;10.1016/0020-708x(84)90184-4;;10.1016/0014-5793(84)80073-3;;6692922;;3495549;;10.1016/0165-5728(87)90092-0;;10.1021/jm991174y;;10821711,"LIU LIMING ET AL: ""Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade"", JOURNAL OF IMMUNOLOGY, vol. 178, no. 8, April 2007 (2007-04-01), pages 5390 - 5398, XP009124948, ISSN: 0022-1767;;RAGHAVAN M ET AL: ""Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand"", IMMUNITY, CELL PRESS, US, vol. 1, no. 4, 1 July 1994 (1994-07-01), pages 303 - 315, XP024247803, ISSN: 1074-7613, [retrieved on 19940701], DOI: 10.1016/1074-7613(94)90082-5;;OLAF STÜVE ET AL: ""Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy: Possible Interventions"", ARCHIVES OF NEUROLOGY, AMERICAN MEDICAL ASSOCIATION, CHICAGO, IL, US, vol. 64, no. 2, 1 February 2007 (2007-02-01), pages 169 - 176, XP008155898, ISSN: 0003-9942, DOI: 10.1001/ARCHNEUR.64.2.169;;REBECCA H. BUCKLEY: ""27. Transplantation immunology: Organ and bone marrow"", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 111, no. 2, 1 February 2003 (2003-02-01), AMSTERDAM, NL, pages S733 - S744, XP055690320, ISSN: 0091-6749, DOI: 10.1067/mai.2003.142;;GERSHONI JONATHAN M ET AL: ""Epitope mapping - The first step in developing epitope-based vaccines"", BIODRUGS, ADIS INTERNATIONAL LTD, NZ, vol. 21, no. 3, 1 January 2007 (2007-01-01), pages 145 - 156, XP009103541, ISSN: 1173-8804, DOI: 10.2165/00063030-200721030-00002;;GETMAN KATE E ET AL: ""Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions"", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 94, no. 4, 1 April 2005 (2005-04-01), pages 718 - 729, XP002417287, ISSN: 0022-3549;;LI NING ET AL: ""Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases"", JOURNAL OF CLINICAL INVESTIGATION, vol. 115, no. 12, December 2005 (2005-12-01), pages 3440 - 3450, XP009124853, ISSN: 0021-9738;;AKILESH SHREERAM ET AL: ""The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease"", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 113, no. 9, 1 May 2004 (2004-05-01), pages 1328 - 1333, XP002417288, ISSN: 0021-9738;;ROOPENIAN DERRY C ET AL: ""FcRn: the neonatal Fc receptor comes of age"", NATURE REVIEWS. IMMUNOLOGY, XX, XX, vol. 7, no. 9, 1 September 2007 (2007-09-01), pages 715 - 725, XP002510057, ISSN: 1474-1733;;RAGHAVAN M ET AL: ""ANALYSIS OF THE PH DEPENDENCE OF THE NEONATAL FC RECEPTOR/IMMUNOGLOBULIN G INTERACTION USING ANTIBODY AND RECEPTOR VARIANTS"", BIOCHEMI, AMERICAN CHEMICAL SOCIETY, US, vol. 34, no. 45, 1 January 1995 (1995-01-01), pages 14649 - 14657, XP009044243, ISSN: 0006-2960, DOI: 10.1021/BI00045A005;;JUNGHANS, IMMUNOLOGIC RESEARCH, vol. 16, no. 1, 1997, pages 29;;JUNGHANSANDERSON, PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 5512;;ROOPENIAN ET AL., J. IMMUNOLOGY, vol. 170, 2003, pages 3528;;BURMEISTER ET AL., NATURE, vol. 372, 1994, pages 366;;LEACH ET AL., J IMMUNOL, vol. 157, 1996, pages 3317;;ISRAEL ET AL., IMMUNOLOGY, vol. 92, 1997, pages 69;;KOBAYASHI ET AL., AM J PHYSIOL, 2002;;RENAL PHYSIOL, vol. 282, 2002, pages F358;;JUNGHANSANDERSON, PROC NATL ACAD SCI US, vol. 93, 1996, pages 5512;;LI ET AL., J CLIN INVEST, vol. 115, 2005, pages 3440 - 3450;;GARRARD ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 1373 - 1377;;CHOTHIA, C. ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281;;BOWIE ET AL., SCIENCE, vol. 247, 1990, pages 1306 - 1310;;A. F. WILLIAMSA. N. BARCLAY, ANN. REV IMMUNOL., vol. 6, 1988, pages 381 - 405;;SZABO ET AL., CURR. OPIN. STRUCT. BIOL., vol. 5, 1995, pages 699 - 705;;A. F. WILLIAMSA. N. BARCLAY, ANN. REV. IMMUNOL., vol. 6, 1988, pages 381 - 405;;CASTAGLIOLA ET AL., J. IMMUNOLOGY, vol. 160, 1998, pages 1458;;MORRISON, S. L., SCIENCE, vol. 229, 1985, pages 1202 - 1207;;DE HAARD ET AL., J. BIOL. CHEM, vol. 274, 1999, pages 18218 - 30;;HOOGENBOOM ET AL., IMMUNOTECHNOLOGY, vol. 4, 1998, pages 1 - 20;;HOOGENBOOM ET AL., IMMUNOL TODAY, vol. 2, 2000, pages 371 - 8;;HAY ET AL., HUM ANTIBOD HYBRIDOMAS, vol. 3, 1992, pages 81 - 85;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;HAWKINS ET AL., J MOL BIOL, vol. 226, 1992, pages 889 - 896;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;GRAM ET AL., PNAS, vol. 89, 1992, pages 3576 - 3580;;HOOGENBOOM ET AL., NUC ACID RES, vol. 19, 1991, pages 4133 - 4137;;MATTHEAKIS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 9022;;HANES ET AL., NAT BIOTECHNOL., vol. 18, 2000, pages 1287 - 92;;HANES ET AL., METHODS ENZYMOL., vol. 328, 2000, pages 404 - 30;;SCHAFFITZEL ET AL., J IMMUNOL METHODS, vol. 231, no. 1-2, 1999, pages 119 - 35;;DE WILDT ET AL., NAT. BIOTECHNOL., vol. 18, 2000, pages 989 - 994;;DE HAARD ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 18218 - 30;;HOOGENBOOM ET AL., IMMUNOL. TODAY, vol. 21, 2000, pages 371 - 378;;KNAPPIK ET AL., J. MOL. BIOL., vol. 296, 2000, pages 57 - 86;;BERGTHORSDOTTIR ET AL., J. IMMUNOL., vol. 166, 2001, pages 2228;;TUOHY ET AL., J. IMMUNOL., vol. 141, 1988, pages 1126 - 1130;;SJOLANDERURBANICZKY, ANAL. CHEM., vol. 63, 1991, pages 2338 - 2345;;GREEN ET AL., NAT. GEN., vol. 7, 1994, pages 13 - 21;;OI ET AL., BIOTECHNIQUES, vol. 4, 1986, pages 214;;TOMLINSON, I.A. ET AL., J. MOL. BIOL., vol. 227, 1992, pages 776 - 798;;COOK, G. P. ET AL., IMMUNOL. TODAY, vol. 16, no. 5, 1995, pages 237 - 242;;CHOTHIA, D. ET AL., J. MOL. BIO., vol. 227, 1992, pages 799 - 817;;TOMLINSON ET AL., EMBO J., vol. 14, no. 18, 1995, pages 4628 - 3;;TOMLINSON ET AL., EMBOJ., vol. 14, no. 18, 1995, pages 4628 - 38;;POWERS ET AL., J. IMMUNOL. METHODS, vol. 251, 2001, pages 123 - 35;;URLAUBCHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;KAUFMANSHARP, MOL. BIOL., vol. 159, 1982, pages 601 621;;BURTONWOOF, ADV. IMMUNOL., vol. 51, 1992, pages 1 - 84;;JEFFERIS ET AL., IMMUNOL. REV., vol. 163, 1998, pages 59 - 76;;BERGE, S.M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;V.V. RANADE, J. CLIN. PHARMACOL., vol. 29, 1989, pages 685;;A.R. BRADWELL ET AL.: ""Monoclonal Antibodies for Cancer Detection and Therapy"", 1985, ACADEMIC PRESS, article ""Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy"", pages: 303 316;;MULLIGAN T ET AL., CLIN. CANC. RES., vol. 1, 1995, pages 1447 - 1454;;MEREDITH RF ET AL., J. NUCL. MED., vol. 37, 1996, pages 1491 - 1496;;ALVAREZ RD ET AL., GYNECOL. ONCOL., vol. 65, 1997, pages 94 - 101;;POSER ET AL., ANN. NEUROL., vol. 13, 1983, pages 227;;MS. MCDONALD ET AL.: ""Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis"", ANN NEUROL, vol. 50, 2001, pages 121 - 127, XP009053064, DOI: 10.1002/ana.1032;;KURTZKE, NEUROLOGY, vol. 33, 1983, pages 1444;;KURTZKE, ANN. NEUROL., vol. 36, 1994, pages 573 - 79;;SOBEL ET AL., J. IMMUNOL., vol. 132, 1984, pages 2393 - 2401;;TRAUGOTT, CELL IMMUNOL., vol. 119, 1989, pages 114 - 129;;WALMSLEY ET AL., GUT, vol. 43, no. l, July 1998 (1998-07-01), pages 29 - 32;;JOWETT ET AL., SCAND J GASTROENTEROL., vol. 38, no. 2, 2003, pages 164 - 71;;KHATRI ET AL., NEUROLOGY, vol. 72, 2009, pages 402 - 409;;STRYER, SCIENCE, vol. 162, 1968, pages 526;;BRAND, L. ET AL., ANNU. REV. BIOCHEM., vol. 41, 1972, pages 843 868;;LUEKING ET AL., ANAL. BIOCHEM., vol. 270, 1999, pages 103 - 111;;GE, NUCLEIC ACIDS RES., vol. 28, 2000, pages e3,I - VII;;MACBEATHSCHREIBER, SCIENCE, vol. 289, 2000, pages 1760 - 1763;;HNATOWICH, D.J. ET AL., J. IMMUNOL. METHODS, vol. 65, 1983, pages 147 157;;D. COLCHER ET AL., METH. ENZYMOL., vol. 121, 1986, pages 802 816;;GODING, J.W.: ""Monoclonal antibodies : principles and practice : production and application of monoclonal antibodies in cell biology, biochemistry, and immunology"", 1986, ACADEMIC PRESS, pages: 124 126;;HUNTERGREENWOOD, NATURE, vol. 144, 1962, pages 945;;DAVID ET AL., BIOCHEMISTRY, vol. 13, 1974, pages 1014 1021;;GREENWOOD, F. ET AL., BIOCHEM. J., vol. 89, 1963, pages 114 123;;MARCHALONIS, J., BIOCHEM. J., vol. 113, 1969, pages 299 305;;MORRISON, M. ET AL., IMMUNOCHEMISTRY, 1971, pages 289 297;;PYKETT, SCI. AM., vol. 246, 1982, pages 78 88 - 123;;HNATOWICH, D. ET AL., J. APPLIED RADIATION, vol. 35, 1984, pages 554 557;;BUCKLEY, R. G. ET AL., F.E.B.S., vol. 166, 1984, pages 202 204;;WAYNE M. YOKOYAMA: ""Current Protocol of Immunology"", 1992, JOHN WILEY AND SON INC., pages: 149 - 156;;SOCRATES ET AL., JOURNAL OF NEUROIMMUNOLOGY, vol. 15, 1987, pages 185 - 194;;FROSTELL-KARLSSON ET AL., J. MED. CHEM., vol. 43, 2000, pages 1986 - 1992",PENDING
6,EP,B8,EP 2310415 B8,128-856-704-807-671,2017-12-13,2017,EP 09734929 A,2009-04-24,US 2009/0002536 W;;US 4815208 P;;US 4850008 P,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF,,DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,"DYAX CORPORATION (2016-05-25);;DYAX CORP., BURLINGTON, US (2018-10-15);;BIOVERATIV THERAPEUTICS INC., WALTHAM, US (2021-10-08);;TAKEDA PHARMACEUTICAL COMPANY LIMITED, OSAKA-S, JP (2021-10-08);;BIOVERATIV THERAPEUTICS INC. (2018-08-22);;BIOGEN HEMOPHILIA INC. (2017-11-22);;BIOVERATIV THERAPEUTICS INC.; US (2021-11-05);;DYAX CORP. (2018-08-22)",https://lens.org/128-856-704-807-671,Amended Patent,yes,3,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;G01N33/68,,7,0,,,"LIU LIMING ET AL: ""Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade"" JOURNAL OF IMMUNOLOGY, vol. 178, no. 8, April 2007 (2007-04), pages 5390-5398, XP009124948 ISSN: 0022-1767;;GETMAN KATE E ET AL: ""Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions"" JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 94, no. 4, 1 April 2005 (2005-04-01), pages 718-729, XP002417287 ISSN: 0022-3549;;LI NING ET AL: ""Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases"" JOURNAL OF CLINICAL INVESTIGATION, vol. 115, no. 12, December 2005 (2005-12), pages 3440-3450, XP009124853 ISSN: 0021-9738;;AKILESH SHREERAM ET AL: ""The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease"" JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 113, no. 9, 1 May 2004 (2004-05-01), pages 1328-1333, XP002417288 ISSN: 0021-9738;;ROOPENIAN DERRY C ET AL: ""FcRn: the neonatal Fc receptor comes of age"" NATURE REVIEWS. IMMUNOLOGY, XX, XX, vol. 7, no. 9, 1 September 2007 (2007-09-01), pages 715-725, XP002510057 ISSN: 1474-1733;;LORIN ROSKOS ET AL: ""Molecular Engineering II: Antibody Affinity"", HANDBOOK OF THERAPEUTIC ANTIBODIES, WILEY-VCH, WEINHEIM, no. Part I, Chapter 7, 30 March 2007 (2007-03-30), XP007912251, ISBN: 978-3-527-31453-9 [retrieved on 2008-02-01];;STEPHAN DUEBEL ED - STEFAN DÜBEL: ""Handbook of Therapeutic Antibodies Chapter 6"", 1 January 2007 (2007-01-01), HANDBOOK OF THERAPEUTIC ANTIBODIES, WILEY-VCH, WEINHEIM, PAGE(S) 119 - 144, XP007913671, ISBN: 978-3-527-31453-9",ACTIVE
7,EP,B1,EP 3348573 B1,166-860-954-362-329,2020-04-22,2020,EP 17195757 A,2009-04-24,US 4815208 P;;US 4850008 P;;EP 09734929 A;;US 2009/0002536 W,2008-04-25,METHOD OF PRODUCING ANTIBODIES AGAINST FCRN AND USE THEREOF,,DYAX CORP;;BIOVERATIV THERAPEUTICS INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,"BIOVERATIV THERAPEUTICS INC., WALTHAM, US (2021-10-08);;TAKEDA PHARMACEUTICAL COMPANY LIMITED, OSAKA-S, JP (2021-10-08);;BIOVERATIV THERAPEUTICS INC. (2019-07-17);;DYAX CORP. (2019-07-17)",https://lens.org/166-860-954-362-329,Granted Patent,yes,3,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61P37/00,,8,0,,,"LIU LIMING ET AL: ""Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade"", JOURNAL OF IMMUNOLOGY, vol. 178, no. 8, April 2007 (2007-04), pages 5390-5398, XP009124948, ISSN: 0022-1767;;GETMAN KATE E ET AL: ""Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions"", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 94, no. 4, 1 April 2005 (2005-04-01), pages 718-729, XP002417287, ISSN: 0022-3549;;LI NING ET AL: ""Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases"", JOURNAL OF CLINICAL INVESTIGATION, vol. 115, no. 12, December 2005 (2005-12), pages 3440-3450, XP009124853, ISSN: 0021-9738;;AKILESH SHREERAM ET AL: ""The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease"", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 113, no. 9, 1 May 2004 (2004-05-01), pages 1328-1333, XP002417288, ISSN: 0021-9738;;ROOPENIAN DERRY C ET AL: ""FcRn: the neonatal Fc receptor comes of age"", NATURE REVIEWS. IMMUNOLOGY, XX, XX, vol. 7, no. 9, 1 September 2007 (2007-09-01), pages 715-725, XP002510057, ISSN: 1474-1733;;RAGHAVAN M ET AL: ""ANALYSIS OF THE PH DEPENDENCE OF THE NEONATAL FC RECEPTOR/IMMUNOGLOBULIN G INTERACTION USING ANTIBODY AND RECEPTOR VARIANTS"", BIOCHEMI, AMERICAN CHEMICAL SOCIETY, US, vol. 34, no. 45, 1 January 1995 (1995-01-01), pages 14649-14657, XP009044243, ISSN: 0006-2960, DOI: 10.1021/BI00045A005;;LORIN ROSKOS ET AL: ""Molecular Engineering II: Antibody Affi nity"", HANDBOOK OF THERAPEUTIC ANTIBO, WILEY-VCH, WEINHEIM, no. Part I, Chapter 7, 30 March 2007 (2007-03-30), XP007912251, ISBN: 978-3-527-31453-9 [retrieved on 2008-02-01];;STEPHAN DUEBEL ED - STEFAN DÜBEL: ""Handbook of Therapeutic Antibodies Chapter 6"", 1 January 2007 (2007-01-01), HANDBOOK OF THERAPEUTIC ANTIBO, WILEY-VCH, WEINHEIM, PAGE(S) 119 - 144, XP007913671, ISBN: 978-3-527-31453-9 * p. 119, 1st paragraph; p. 122, first full paragraph *",ACTIVE
8,TW,A,TW 201509430 A,051-689-481-094-549,2015-03-16,2015,TW 103126334 A,2009-04-24,US 4815208 P;;US 4850008 P,2008-04-25,FC receptor binding proteins,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;BIOGEN IDEC HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/051-689-481-094-549,Patent of Addition,no,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,A61K39/395;;A61P37/00;;C12N15/13,,0,0,,,,ACTIVE
9,SG,A1,SG 196839 A1,082-089-460-153-680,2014-02-13,2014,SG 2014004063 A,2009-04-24,US 4815208 P;;US 4850008 P,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF,"ANTIBODIES AGAINST FCRN AND USE THEREOFAbstractThis disclosure provides, inter alia, proteins that bindtoFcRn,e.g.,immunoglobulins that5inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat avarietyofdisorders including autoimmune disorders.Figure 36139",DYAX CORP;;BIOGEN IDEC HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/082-089-460-153-680,Patent Application,no,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,,,0,0,,,,PENDING
10,EP,A1,EP 3348573 A1,179-227-978-064-041,2018-07-18,2018,EP 17195757 A,2009-04-24,US 4815208 P;;US 4850008 P;;EP 09734929 A;;US 2009/0002536 W,2008-04-25,METHOD OF PRODUCING ANTIBODIES AGAINST FCRN AND USE THEREOF,"This disclosure provides,  inter alia , proteins that bind to FcRn,  e.g ., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,"BIOVERATIV THERAPEUTICS INC., WALTHAM, US (2021-10-08);;TAKEDA PHARMACEUTICAL COMPANY LIMITED, OSAKA-S, JP (2021-10-08);;BIOVERATIV THERAPEUTICS INC. (2019-07-17);;DYAX CORP. (2019-07-17)",https://lens.org/179-227-978-064-041,Patent Application,yes,53,0,69,71,190,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61P37/00,,109,84,046-418-619-195-508;;030-199-397-665-51X;;004-906-446-973-883;;085-172-902-751-941;;011-483-806-642-730;;011-052-821-413-843;;000-202-910-533-267;;038-256-556-798-926;;054-019-549-143-703;;120-214-453-828-332;;025-426-299-802-257;;000-782-271-097-14X;;004-906-446-973-883;;049-134-753-209-354;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;048-188-266-680-461;;050-465-090-140-473;;078-075-414-981-82X;;073-188-128-290-445;;009-817-530-258-10X;;029-694-380-116-357;;035-872-873-163-027;;100-049-580-404-573;;033-797-614-829-293;;072-378-691-723-546;;005-119-615-003-591;;034-331-211-704-877;;025-395-146-381-464;;174-783-722-981-415;;011-962-497-035-168;;116-821-682-892-530;;047-865-259-862-039;;006-528-517-743-856;;020-010-536-497-604;;119-013-590-539-100;;029-694-380-116-357;;049-928-993-608-092;;063-830-914-171-200;;101-386-538-214-614;;017-328-464-709-648;;023-676-781-371-861;;092-023-577-402-127;;039-508-259-975-855;;002-664-741-683-318;;021-641-900-032-887;;002-664-741-683-318;;092-023-577-402-127;;021-641-900-032-887;;103-477-074-900-777;;051-940-176-386-905;;029-667-686-534-996;;007-551-089-881-647;;002-237-818-610-496;;007-364-858-655-289;;056-942-841-068-650;;007-178-177-990-322;;136-081-470-295-245;;048-685-340-891-994;;053-356-650-362-67X;;000-025-810-068-033;;035-181-446-169-624;;123-176-483-512-245;;074-644-618-813-918;;077-977-371-680-838;;078-111-943-124-60X;;003-452-898-892-099;;004-863-960-524-08X;;063-137-267-247-313;;095-153-055-114-800;;085-812-916-734-336;;087-617-084-673-049;;039-262-924-716-099;;152-520-430-306-466;;038-308-787-457-936;;035-803-984-874-05X;;008-778-244-900-75X;;000-092-434-393-958;;005-737-717-273-670;;056-726-428-144-81X;;049-415-660-020-852;;070-640-740-750-988;;011-539-181-910-335,10.4049/jimmunol.178.8.5390;;17404325;;15682382;;10.1002/jps.20297;;pmc1280965;;10.1172/jci24394;;16284651;;10.1172/jci200418838;;15124024;;pmc398424;;10.1172/jci18838;;10.1038/nri2155;;17703228;;7578107;;10.1021/bi00045a005;;9048207;;10.1007/bf02786322;;8643606;;pmc39277;;10.1073/pnas.93.11.5512;;12646614;;10.4049/jimmunol.170.7.3528;;8871627;;10.4049/jimmunol.157.8.3317;;10.1046/j.1365-2567.1997.00326.x;;pmc1363983;;9370926;;10.1152/ajprenal.0164.2001;;11788451;;pmc1280965;;10.1172/jci24394;;16284651;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;2315699;;10.1126/science.2315699;;10.1146/annurev.immunol.6.1.381;;3289571;;10.1146/annurev.iy.06.040188.002121;;4001944;;10.1126/science.4001944;;10373423;;10.1074/jbc.274.26.18218;;9661810;;10.1016/s1380-2933(98)00007-4;;10.1016/s0167-5699(00)01667-4;;10916139;;1367769;;10.1038/nbt1291-1369;;1385989;;10.3233/hab-1992-3204;;2531466;;10.1126/science.2531466;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;10.1038/352624a0;;1907718;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1038/nbt1291-1373;;1369462;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;7522328;;10.1073/pnas.91.19.9022;;pmc44739;;11101809;;10.1038/82407;;10.1016/s0076-6879(00)28409-7;;11075357;;10.1016/s0022-1759(99)00149-0;;10648932;;10.1038/79494;;10973222;;10.1016/s0167-5699(00)01667-4;;10916139;;10656818;;10.1006/jmbi.1999.3444;;11160276;;10.4049/jimmunol.166.4.2228;;1759716;;10.1021/ac00020a025;;10.1016/0959-440x(95)80064-6;;8574707;;10.1126/science.3929380;;3929380;;1404388;;10.1016/0022-2836(92)90223-7;;7779254;;10.1016/0167-5699(95)80166-9;;10.1016/0022-2836(92)90224-8;;1404389;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;10.1016/0022-2836(92)90224-8;;1404389;;1404388;;10.1016/0022-2836(92)90223-7;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;10.1016/s0022-1759(00)00290-8;;11292488;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;10.1016/s0065-2776(08)60486-1;;1502974;;9700502;;10.1111/j.1600-065x.1998.tb01188.x;;10.1002/jps.2600660104;;833720;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;9815943;;8790200;;10.1006/gyno.1996.4577;;9103398;;6847134;;10.1002/ana.410130302;;10.1002/ana.1032;;11456302;;6685237;;10.1212/wnl.33.11.1444;;2456341;;6371137;;10.1016/0008-8749(89)90228-1;;2784075;;10.1136/gut.43.1.29;;pmc1727189;;9771402;;10.1080/00365520310000654;;12678333;;19188571;;10.1212/01.wnl.0000341766.59028.9d;;pmc2677532;;10.1126/science.162.3853.526;;5706935;;4563443;;10.1146/annurev.bi.41.070172.004211;;10328771;;10.1006/abio.1999.4063;;10976071;;10.1126/science.289.5485.1760;;10.1016/0076-6879(86)21078-2;;3724495;;4360349;;10.1021/bi00702a028;;10.1042/bj0890114;;14097352;;pmc1202279;;4185494;;10.1042/bj1130299;;pmc1184636;;10.1016/0019-2791(71)90484-8;;5170158;;6655236;;10.1016/0022-1759(83)90311-3;;6547405;;10.1016/0020-708x(84)90184-4;;10.1016/0014-5793(84)80073-3;;6692922;;7079720;;10.1038/scientificamerican0582-78;;3495549;;10.1016/0165-5728(87)90092-0;;10.1021/jm991174y;;10821711,"LIU LIMING ET AL: ""Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade"", JOURNAL OF IMMUNOLOGY, vol. 178, no. 8, April 2007 (2007-04-01), pages 5390 - 5398, XP009124948, ISSN: 0022-1767;;GETMAN KATE E ET AL: ""Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions"", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 94, no. 4, 1 April 2005 (2005-04-01), pages 718 - 729, XP002417287, ISSN: 0022-3549;;LI NING ET AL: ""Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases"", JOURNAL OF CLINICAL INVESTIGATION, vol. 115, no. 12, December 2005 (2005-12-01), pages 3440 - 3450, XP009124853, ISSN: 0021-9738;;AKILESH SHREERAM ET AL: ""The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease"", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 113, no. 9, 1 May 2004 (2004-05-01), pages 1328 - 1333, XP002417288, ISSN: 0021-9738;;ROOPENIAN DERRY C ET AL: ""FcRn: the neonatal Fc receptor comes of age"", NATURE REVIEWS. IMMUNOLOGY, XX, XX, vol. 7, no. 9, 1 September 2007 (2007-09-01), pages 715 - 725, XP002510057, ISSN: 1474-1733;;RAGHAVAN M ET AL: ""ANALYSIS OF THE PH DEPENDENCE OF THE NEONATAL FC RECEPTOR/IMMUNOGLOBULIN G INTERACTION USING ANTIBODY AND RECEPTOR VARIANTS"", BIOCHEMI, AMERICAN CHEMICAL SOCIETY, US, vol. 34, no. 45, 1 January 1995 (1995-01-01), pages 14649 - 14657, XP009044243, ISSN: 0006-2960, DOI: 10.1021/BI00045A005;;LORIN ROSKOS ET AL: ""Molecular Engineering II: Antibody Affi nity"", HANDBOOK OF THERAPEUTIC ANTIBO, WILEY-VCH, WEINHEIM, no. Part I, Chapter 7, 30 March 2007 (2007-03-30), XP007912251, ISBN: 978-3-527-31453-9, [retrieved on 20080201];;STEPHAN DUEBEL ED - STEFAN DÜBEL: ""Handbook of Therapeutic Antibodies Chapter 6"", 1 January 2007, HANDBOOK OF THERAPEUTIC ANTIBO, WILEY-VCH, WEINHEIM, PAGE(S) 119 - 144, ISBN: 978-3-527-31453-9, XP007913671;;JUNGHANS, IMMUNOLOGIC RESEARCH, vol. 16, no. 1, 1997, pages 29;;JUNGHANS; ANDERSON, PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 5512;;ROOPENIAN ET AL., J. IMMUNOLOGY, vol. 170, 2003, pages 3528;;BURMEISTER ET AL., NATURE, vol. 372, 1994, pages 366;;LEACH ET AL., J IMMUNOL, vol. 157, 1996, pages 3317;;ISRAEL ET AL., IMMUNOLOGY, vol. 92, 1997, pages 69;;KOBAYASHI ET AL., AM J PHYSIOL, 2002;;RENAL PHYSIOL, vol. 282, 2002, pages F358;;LI ET AL., J CLIN INVEST, vol. 115, 2005, pages 3440 - 3450;;KABAT, E.A. ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, NIH;;CHOTHIA, C. ET AL.: ""J. Mol. Biol."", vol. 196, 1987, pages: 901 - 917;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;""Current Protocols in Molecular Biology"", 1989, JOHN WILEY & SONS, pages: 6.3.1 - 6.3.6;;BOWIE ET AL., SCIENCE, vol. 247, 1990, pages 1306 - 1310;;A. F. WILLIAMS; A. N. BARCLAY, ANN. REV IMMUNOL., vol. 6, 1988, pages 381 - 405;;""Antibody Engineering"", 1995, OXFORD UNIVERSITY PRESS;;HARLOW ET AL.: ""Antibodies A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY;;CASTAGLIOLA ET AL., J. IMMUNOLOGY, vol. 160, 1998, pages 1458;;SMITH, SCIENCE, vol. 228, 1985, pages 1315 - 1317;;DE HAARD ET AL., J. BIOL. CHEM, vol. 274, 1999, pages 18218 - 18230;;HOOGENBOOM ET AL., IMMUNOTECHNOLOGY, vol. 4, 1998, pages 1 - 20;;HOOGENBOOM ET AL., IMMUNOL TODAY, vol. 2, 2000, pages 371 - 378;;FUCHS ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 1370 - 1372;;HAY ET AL., HUM ANTIBOD HYBRIDOMAS, vol. 3, 1992, pages 81 - 85;;HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;HAWKINS ET AL., J MOL BIOL, vol. 226, 1992, pages 889 - 896;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;GRAM ET AL., PNAS, vol. 89, 1992, pages 3576 - 3580;;GARRARD ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 1373 - 1377;;HOOGENBOOM ET AL., NUC ACID RES, vol. 19, 1991, pages 4133 - 4137;;MATTHEAKIS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 9022;;HANES ET AL., NAT BIOTECHNOL., vol. 18, 2000, pages 1287 - 1292;;HANES ET AL., METHODS ENZYMOL., vol. 328, 2000, pages 404 - 430;;SCHAFFITZEL ET AL., J IMMUNOL METHODS., vol. 231, no. 1-2, 1999, pages 119 - 135;;DE WILDT ET AL., NAT. BIOTECHNOL., vol. 18, 2000, pages 989 - 994;;A. F. WILLIAMS; A. N. BARCLAY, ANN. REV. IMMUNOL., vol. 6, 1988, pages 381 - 405;;DE HAARD ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 18218 - 18230;;HOOGENBOOM ET AL., IMMUNOL. TODAY, vol. 21, 2000, pages 371 - 378;;KNAPPIK ET AL., J. MOL. BIOL., vol. 296, 2000, pages 57 - 86;;BERGTHORSDOTTIR ET AL., J. IMMUNOL., vol. 166, 2001, pages 2228;;RAETHER: ""Surface Plasmons"", 1988, SPRINGER VERLAG;;SJOLANDER; URBANICZKY, ANAL. CHEM., vol. 63, 1991, pages 2338 - 2345;;SZABO ET AL., CURR. OPIN. STRUCT. BIOL., vol. 5, 1995, pages 699 - 705;;GREEN ET AL., NAT. GEN., vol. 7, 1994, pages 13 - 21;;MORRISON, S. L., SCIENCE, vol. 229, 1985, pages 1202 - 1207;;OI ET AL., BIOTECHNIQUES, vol. 4, 1986, pages 214;;TOMLINSON, I.A. ET AL., J. MOL. BIOL., vol. 227, 1992, pages 776 - 798;;COOK, G. P. ET AL., IMMUNOL. TODAY, vol. 16, no. 5, 1995, pages 237 - 242;;CHOTHIA, D. ET AL., J. MOL. BIO., vol. 227, 1992, pages 799 - 817;;TOMLINSON ET AL., EMBO J., vol. 14, no. 18, 1995, pages 4628 - 4623;;CHOTHIA ET AL., J. MOL. BIOL., vol. 227, 1992, pages 799 - 817;;TOMLINSON ET AL., J. MOL. BIOL., vol. 227, 1992, pages 776 - 798;;TOMLINSON ET AL., EMBOJ., vol. 14, no. 18, 1995, pages 4628 - 4638;;POWERS ET AL., J. IMMUNOL. METHODS, vol. 251, 2001, pages 123 - 135;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;KAUFMAN; SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;BURTON; WOOF, ADV. IMMUNOL., vol. 51, 1992, pages 1 - 84;;JEFFERIS ET AL., IMMUNOL. REV., vol. 163, 1998, pages 59 - 76;;BERGE, S.M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;V.V. RANADE, J. CLIN. PHARMACOL., vol. 29, 1989, pages 685;;S.E. ORDER ET AL.: ""Monoclonal Antibodies for Cancer Detection and Therapy"", 1985, ACADEMIC PRESS, article ""Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy"", pages: 303 - 316;;MULLIGAN T ET AL., CLIN. CANC. RES., vol. 1, 1995, pages 1447 - 1454;;MEREDITH RF ET AL., J. NUCL. MED., vol. 37, 1996, pages 1491 - 1496;;ALVAREZ RD ET AL., GYNECOL. ONCOL., vol. 65, 1997, pages 94 - 101;;POSER ET AL., ANN. NEUROL., vol. 13, 1983, pages 227;;MS. MCDONALD ET AL.: ""Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis"", ANN NEUROL, vol. 50, 2001, pages 121 - 127, XP009053064, DOI: doi:10.1002/ana.1032;;KURTZKE, NEUROLOGY, vol. 33, 1983, pages 1444;;KURTZKE, ANN. NEUROL., vol. 36, 1994, pages 573 - 79;;TUOHY ET AL., J. IMMUNOL., vol. 141, 1988, pages 1126 - 1130;;SOBEL ET AL., J. IMMUNOL., vol. 132, 1984, pages 2393 - 2401;;TRAUGOTT, CELL IMMUNOL., vol. 119, 1989, pages 114 - 129;;WALMSLEY ET AL., GUT., vol. 43, no. l, July 1998 (1998-07-01), pages 29 - 32;;JOWETT ET AL., SCAND J GASTROENTEROL., vol. 38, no. 2, 2003, pages 164 - 171;;KHATRI ET AL., NEUROLOGY, vol. 72, 2009, pages 402 - 409;;STRYER, SCIENCE, vol. 162, 1968, pages 526;;BRAND, L. ET AL., ANNU. REV. BIOCHEM., vol. 41, 1972, pages 843 - 868;;LUEKING ET AL., ANAL. BIOCHEM., vol. 270, 1999, pages 103 - 111;;GE, NUCLEIC ACIDS RES., vol. 28, no. e3, 2000, pages I - VII;;MACBEATH; SCHREIBER, SCIENCE, vol. 289, 2000, pages 1760 - 1763;;WENSEL; MEARES: ""Radioimmunoimaging and Radioimmunotherapy"", 1983, ELSEVIER;;D. COLCHER ET AL., METH. ENZYMOL., vol. 121, 1986, pages 802 - 816;;GODING, J.W.: ""Monoclonal antibodies : principles and practice : production and application of monoclonal antibodies in cell biology, biochemistry, and immunology"", 1986, ACADEMIC PRESS, pages: 124 - 126;;HUNTER; GREENWOOD, NATURE, vol. 144, 1962, pages 945;;DAVID ET AL., BIOCHEMISTRY, vol. 13, 1974, pages 1014 - 1021;;GREENWOOD, F. ET AL., BIOCHEM. J., vol. 89, 1963, pages 114 - 123;;MARCHALONIS, J., BIOCHEM. J., vol. 113, 1969, pages 299 - 305;;MORRISON, M. ET AL., IMMUNOCHEMISTRY, 1971, pages 289 - 297;;BURCHIEL, S. ET AL: ""Tumor Imaging: The Radioimmunochemical Detection of Cancer"", 1982;;HNATOWICH, D.J. ET AL.: ""J. Immunol. Methods"", vol. 65, 1983, pages: 147 - 157;;HNATOWICH, D. ET AL., J. APPLIED RADIATION, vol. 35, 1984, pages 554 - 557;;BUCKLEY, R. G. ET AL., F.E.B.S., vol. 166, 1984, pages 202 - 204;;A.R. BRADWELL ET AL.: ""Monoclonal Antibodies for Cancer Detection and Therapy"", 1985, ACADEMIC PRESS, article ""Developments in Antibody Imaging"", pages: 65 - 85;;PYKETT, SCI. AM., vol. 246, 1982, pages 78 - 88;;WAYNE M. YOKOYAMA: ""Current Protocol of Immunology"", JOHN WILEY AND SON INC.;;""Monoclonal Antibodies"", 1992, SPRINGER-VERLAG, pages: 149 - 156;;SOCRATES ET AL., JOURNAL OF NEUROIMMUNOLOGY, vol. 15, 1987, pages 185 - 194;;FROSTELL-KARLSSON ET AL., J. MED. CHEM., vol. 43, 2000, pages 1986 - 1992",ACTIVE
11,KR,A,KR 20190104432 A,024-585-136-504-230,2019-09-09,2019,KR 20197025353 A,2009-04-24,US 4815208 P;;US 4850008 P;;US 2009/0002536 W,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF,"본 발명에서는 특히, FcRn에 결합하는 단백질, 예를 들면, 높은 친화성 (affinity)과 선택성 (selectivity)으로 FcRn을 저해하는 면역글로불린을 제시한다. 이들 FcRn-결합 단백질은 자가면역 질환을 비롯한 다양한 질환을 치료하는데 이용될 수 있다.",DYAX CORP;;BIOVERATIV THERAPEUTICS INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/024-585-136-504-230,Patent Application,no,0,0,69,71,380,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,A61K39/395;;C07K16/28;;C12N15/09,,0,0,,,,DISCONTINUED
12,EP,A2,EP 2310415 A2,096-255-023-462-548,2011-04-20,2011,EP 09734929 A,2009-04-24,US 2009/0002536 W;;US 4815208 P;;US 4850008 P,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF,,DYAX CORP;;BIOGEN IDEC HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,"DYAX CORPORATION (2016-05-25);;DYAX CORP., BURLINGTON, US (2018-10-15);;BIOVERATIV THERAPEUTICS INC., WALTHAM, US (2021-10-08);;TAKEDA PHARMACEUTICAL COMPANY LIMITED, OSAKA-S, JP (2021-10-08);;BIOVERATIV THERAPEUTICS INC. (2018-08-22);;BIOGEN HEMOPHILIA INC. (2017-11-22);;BIOVERATIV THERAPEUTICS INC.; US (2021-11-05);;DYAX CORP. (2018-08-22)",https://lens.org/096-255-023-462-548,Patent Application,yes,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;G01N33/68,,0,0,,,,ACTIVE
13,CN,A,CN 104479017 A,170-730-652-267-923,2015-04-01,2015,CN 201410357602 A,2009-04-24,US 4815208 P;;US 4850008 P,2008-04-25,Antibodies against FCRN and use thereof,"The invention refers to antibodies against FCRN and use thereof, and provides a separated antibody comprising a heavy chain (HC) immune globulin variable domain sequence, and a light chain (LC) immune globulin variable domain sequence, wherein the HC and LC immune globulin variable domain sequences form antigen-binding sites jointing with a human FCRN. FCRN binding proteins can be used for treating a variety of disorders including autoimmune disorders.",DYAX CORP;;SYNTONIX PHARMACEUTICALS INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/170-730-652-267-923,Patent Application,no,0,5,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61K39/395;;A61P37/00;;G01N33/68,,0,0,,,,DISCONTINUED
14,JP,A,JP 2017029149 A,160-362-525-199-949,2017-02-09,2017,JP 2016155218 A,2016-08-08,US 4815208 P;;US 4850008 P,2008-04-25,ANTIBODY AGAINST FCRN AND USE THEREOF,"PROBLEM TO BE SOLVED: To provide antibodies against FcRn, pharmaceutical compositions comprising the same, and use thereof.SOLUTION: An isolated antibody comprises a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, where the heavy chain and light chain immunoglobulin variable domain sequences form an antigen binding site that binds to human FcRn.SELECTED DRAWING: Figure 36",DYAX CORP;;BIOGEN IDEC HEMOPHILIA INC,CHRISTOPHER TENHOOR;;ARUMUGAM MURUGANANDAM;;LADNER ROBERT CHARLES;;CLIVE WOOD;;ALAN J BITONTI;;JAMES STATTEL;;KEVIN MCDONNELL;;LIU LIMIN;;JENNIFER DUMONT;;AARON SATO,,https://lens.org/160-362-525-199-949,Patent Application,no,3,0,69,71,190,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C12N15/09;;A61K39/395;;A61K45/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/04;;A61P9/00;;A61P13/12;;A61P17/00;;A61P19/02;;A61P21/04;;A61P25/00;;A61P25/14;;A61P29/00;;A61P37/02;;A61P37/06;;C07K16/18;;C07K16/28;;C07K16/46;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/02;;G01N33/53,,0,0,,,,ACTIVE
15,TW,B,TW I453031 B,182-194-048-318-033,2014-09-21,2014,TW 98113830 A,2009-04-24,US 4815208 P;;US 4850008 P,2008-04-25,Fc receptor binding proteins,,DYAX CORP;;BIOGEN IDEC HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/182-194-048-318-033,Granted Patent,no,3,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,,,0,0,,,,ACTIVE
16,TW,A,TW 201010720 A,003-117-470-411-698,2010-03-16,2010,TW 98113830 A,2009-04-24,US 4815208 P;;US 4850008 P,2008-04-25,Fc receptor binding proteins,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;SYNTONIX PHARMACEUTICALS INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/003-117-470-411-698,Patent of Addition,no,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,A61K39/395;;A61P37/00;;C12N15/13,,0,0,,,,ACTIVE
17,TW,B,TW I547287 B,012-826-500-612-094,2016-09-01,2016,TW 103126334 A,2009-04-24,US 4815208 P;;US 4850008 P,2008-04-25,Fc receptor binding proteins,,DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/012-826-500-612-094,Granted Patent,no,2,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,,,0,0,,,,ACTIVE
18,SG,A,SG 10202105499W A,069-622-933-148-761,2021-07-29,2021,SG 10202105499W A,2009-04-24,US 4815208 P;;US 4850008 P,2008-04-25,Antibodies Against Fcrn And Use Thereof,,DYAX CORP;;BIOVERATIV THERAPEUTICS INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/069-622-933-148-761,Unknown,no,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,,,0,0,,,,PENDING
19,KR,A,KR 20160079912 A,094-442-664-973-437,2016-07-06,2016,KR 20167016843 A,2009-04-24,US 4815208 P;;US 4850008 P;;US 2009/0002536 W,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF,"본 발명에서는 특히, FcRn에 결합하는 단백질, 예를 들면, 높은 친화성 (affinity)과 선택성 (selectivity)으로 FcRn을 저해하는 면역글로불린을 제시한다. 이들 FcRn-결합 단백질은 자가면역 질환을 비롯한 다양한 질환을 치료하는데 이용될 수 있다.",DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/094-442-664-973-437,Patent Application,no,0,0,69,71,380,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,A61K39/395;;C12N15/09,,0,0,,,,ACTIVE
20,BR,B1,BR 122021026834 B1,171-098-860-080-143,2022-11-08,2022,BR 122021026834 A,2009-04-24,US 2009/0002536 W;;US 4815208 P;;US 4850008 P,2008-04-25,"ANTICORPOS ISOLADOS QUE SE LIGAM A FCRN, COMPOSIÇÃO FARMACÊUTICA QUE COMPREENDE OS MESMOS E MÉTODOS PARA DETECTAR E PARA MODULAR FCRN","Esta divulgação fornece, entre outras coisas, proteínas que se ligam a FcRn, por exemplo, imunoglobulinas, que inibem FcRn com alta afinidade e seletividade. As proteínas que se ligam a FcRn podem ser usadas para tratar uma variedade de distúrbios, incluindo distúrbios autoimunes.",TAKEDA PHARMACEUTICALS CO;;BIOVERATIV THERAPEUTICS INC,CHRISTOPHER TENHOOR;;ARUMUGAM MURUGANANDAM;;ROBERT CHARLES LADNER;;CLIVE WOOD;;ALAN J BITONTI;;JAMES STATTEL;;KEVIN MCDONNELL;;LIMING LIU;;JENNIFER DUMONT;;AARON SATO,,https://lens.org/171-098-860-080-143,Granted Patent,no,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61P37/00,,0,0,,,,ACTIVE
21,US,B2,US 8273351 B2,196-933-794-730-075,2012-09-25,2012,US 42952909 A,2009-04-24,US 42952909 A;;US 4815208 P;;US 4850008 P,2008-04-25,Fc receptor binding proteins,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON;;DYAX CORP;;SYNTONIX PHARMACEUTICALS INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,DYAX CORPORATION (2012-09-17);;BIOGEN HEMOPHILIA INC (2009-06-30);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021-02-26);;DYAX CORP (2009-06-25),https://lens.org/196-933-794-730-075,Granted Patent,yes,10,13,69,71,190,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,A61K39/395;;C07H21/00;;C07K16/00;;G01N33/53,424/133.1;;530/389.1,27,27,027-477-313-726-928;;095-334-545-560-259;;014-113-432-888-031;;045-942-104-775-903;;051-707-000-800-833;;031-100-076-670-370;;001-779-867-387-972;;013-142-717-038-23X;;006-553-734-546-212;;068-238-957-669-243;;105-316-874-895-908;;033-368-627-556-233;;053-851-713-620-401;;029-611-134-469-353;;085-172-902-751-941;;030-199-397-665-51X;;046-418-619-195-508;;011-483-806-642-730;;099-539-944-702-597;;036-929-348-767-907;;025-426-299-802-257;;000-202-910-533-267;;038-256-556-798-926;;000-782-271-097-14X;;120-214-453-828-332;;004-906-446-973-883;;054-019-549-143-703,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1006/jmbi.1996.0548;;8876650;;12218124;;10.4049/jimmunol.169.6.3076;;12850000;;10.1016/s0006-291x(03)01131-8;;12079396;;10.1016/s0022-2836(02)00264-4;;16989900;;10.1016/j.molimm.2006.08.001;;10.1006/jmbi.1999.3192;;10543973;;10556035;;10.1006/jmbi.1999.3141;;8424945;;10.1021/bi00055a024;;10556249;;10.1093/protein/12.10.879;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.1016/s0161-5890(98)00095-9;;10199394;;10586066;;10.4049/jimmunol.163.12.6694;;7516563;;10.1016/s0923-2494(94)80039-1;;10.1172/jci200418838;;15124024;;pmc398424;;10.1172/jci18838;;15682382;;10.1002/jps.20297;;10.4049/jimmunol.178.8.5390;;17404325;;10.1038/nri2155;;17703228;;10.1056/nejm199901213400311;;9895405;;10.2210/pdb1frt/pdb;;10.1038/372379a0;;7969498;;10.1046/j.1365-2567.1997.00326.x;;pmc1363983;;9370926;;9048207;;10.1007/bf02786322;;8643606;;pmc39277;;10.1073/pnas.93.11.5512;;10.1152/ajprenal.0164.2001;;11788451;;8871627;;10.4049/jimmunol.157.8.3317;;pmc1280965;;10.1172/jci24394;;16284651;;12646614;;10.4049/jimmunol.170.7.3528,"Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979).;;MacCallum et al. (J. Mol. Biol. (1996) 262:732-745).;;De Pascalis et al. The Journal of Immunology (2002) 169, 3076-3084.;;Casset et al. ((2003) BBRC 307, 198-205).;;Vajdos et al. ((2002) J. Mol. Biol. 320, 415-428).;;Holm et al ((2007) Mol. Immunol. 44: 1075-1084).;;Chen et al. J. Mol. Bio. (1999) 293, 865-881.;;Wu et al. (J. Mol. Biol. (1999) 294, 151-162).;;Brummell et al. (Biochemistry 32:1180-1187 (1993)).;;Kobayashi et al. (Protein Engineering 12:879-844 (1999)).;;Burks et al. (PNAS 94:412-417 (1997)).;;Jang et al. (Molec. Immunol. 35:1207-1217 (1998)).;;Brorson et al. (J. Immunol. 163:6694-6701 (1999)).;;Coleman (Research in Immunol. 145:33-36 (1994)).;;Akilesh et al., The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest. May 2004;113(9):1328-33.;;Getman et al., Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. J Pharm Sci. Apr. 2005;94(4):718-29.;;Liu et al., Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. J Immunol. Apr. 15, 2007;178(8):5390-8.;;Roopenian et al., FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. Sep. 2007;7(9):715-25. Epub Aug. 17, 2007.;;Yu, Zhiya and Lennon, Vanda; ""Mechanism of Intravenous Immune Globulin Therapy in Antibody-Mediated Autoimmune Diseases""; The New England Journal of Medicine, Clinical Implications of Basic Research; (1999); 34(3): 227-228.;;Burmeister et al., Crystal structure of the complex of rat neonatal Fc receptor with Fc, Nature 372:366 (1994).;;Israel et al., Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells, Immunology 92:69 (1997).;;Junghans, Finally! The Brambell Receptor (FcRB), Immunologic Research 16(1):29-57 (1997).;;Junghans et al., The protection receptor for IgG catabolism is the beta-microglobulin-containing neonatal intestinal transport receptor, Proc. Natl. Acad. Sci. USA 93:5512-5516 (1996).;;Kobayashi et al., FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells, Am J Physiol Renal Physiol 282:F358 (2002).;;Leach et al., Isolation from Human Placenta of the IgG Transporter, FcRn, and Localization to the Syncytiotrophoblast, J Immunol 157:3317 (1996).;;Li et al., Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases, J Clin Invest 115:3440-3450 (2005).;;Roopenian et al., The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostatis, and Fate of IgG-Fc-Coupled Drugs, J. Immunology 170:3528 (2003).",ACTIVE
22,KR,A,KR 20170122286 A,080-922-850-346-95X,2017-11-03,2017,KR 20177030420 A,2009-04-24,US 4815208 P;;US 4850008 P;;US 2009/0002536 W,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF,"본 발명에서는 특히, FcRn에 결합하는 단백질, 예를 들면, 높은 친화성 (affinity)과 선택성 (selectivity)으로 FcRn을 저해하는 면역글로불린을 제시한다. 이들 FcRn-결합 단백질은 자가면역 질환을 비롯한 다양한 질환을 치료하는데 이용될 수 있다.",DYAX CORP;;BIOVERATIV THERAPEUTICS INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/080-922-850-346-95X,Patent Application,no,9,0,69,71,380,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61K39/395;;C12N15/09,,0,0,,,,ACTIVE
23,US,A1,US 2009/0324614 A1,152-141-730-913-612,2009-12-31,2009,US 42952909 A,2009-04-24,US 42952909 A;;US 4815208 P;;US 4850008 P,2008-04-25,FC RECEPTOR BINDING PROTEINS,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;SYNTONIX PHARMACEUTICALS INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,DYAX CORPORATION (2012-09-17);;BIOGEN HEMOPHILIA INC (2009-06-30);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021-02-26);;DYAX CORP (2009-06-25),https://lens.org/152-141-730-913-612,Patent Application,yes,7,11,69,71,190,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,A61K39/395;;A61P37/00;;C07H21/00;;C07K16/00;;G01N33/53,424/172.1;;530/389.1;;536/23.53;;436/501,0,0,,,,ACTIVE
24,CA,A1,CA 3131470 A1,177-014-738-247-998,2009-10-29,2009,CA 3131470 A,2009-04-24,US 4815208 P;;US 4850008 P;;CA 2722082 A,2008-04-25,FC RECEPTOR BINDING PROTEINS,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",TAKEDA PHARMACEUTICALS CO;;BIOVERATIV THERAPEUTICS INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/177-014-738-247-998,Patent Application,no,0,0,69,71,190,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61K39/395;;A61P37/06;;C12N15/13,,0,0,,,,PENDING
25,JP,A,JP 2015143230 A,146-768-078-895-952,2015-08-06,2015,JP 2015027638 A,2015-02-16,US 4815208 P;;US 4850008 P,2008-04-25,ANTIBODIES AGAINST FCRN AND USES THEREOF,"PROBLEM TO BE SOLVED: To provide isolated antibodies to FcRn, pharmaceutical compositions thereof, uses thereof and a detection method of FcRn, as well as methods for treating autoimmune disorders and modulating symptoms thereof by administering the antibody to modulate FcRn activity.SOLUTION: Provided is an isolated antibody comprising a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, where the heavy chain and light chain immunoglobulin variable domain sequences form an antigen binding site that binds to human FcRn. Also provided is a pharmaceutical composition comprising the antibody and a pharmaceutically acceptable carrier.",DYAX CORP;;BIOGEN IDEC HEMOPHILIA INC,CHRISTOPHER TENHOOR;;ARUMUGAM MURUGANANDAM;;LADNER ROBERT CHARLES;;CLIVE WOOD;;ALAN J BITONTI;;JAMES STATTEL;;KEVIN MCDONNELL;;LIU LIMIN;;JENNIFER DUMONT;;AARON SATO,,https://lens.org/146-768-078-895-952,Patent Application,no,5,0,69,71,190,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61K39/39;;A61K39/395;;A61K45/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/04;;A61P9/00;;A61P13/12;;A61P17/00;;A61P19/02;;A61P21/04;;A61P25/00;;A61P25/14;;A61P29/00;;A61P37/06;;C07K16/46;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/02;;C12N15/09;;G01N33/53;;G01N33/532,,0,0,,,,ACTIVE
26,WO,A2,WO 2009/131702 A2,045-914-659-775-378,2009-10-29,2009,US 2009/0002536 W,2009-04-24,US 4815208 P;;US 4850008 P,2008-04-25,FC RECEPTOR BINDING PROTEINS,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g. , immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;SYNTONIX PHARMACEUTICALS INC;;TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/045-914-659-775-378,Patent Application,yes,0,63,69,71,190,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/00,,0,0,,,,PENDING
27,TW,B,TW I593423 B,071-787-938-915-904,2017-08-01,2017,TW 105116324 A,2009-04-24,US 4815208 P;;US 4850008 P,2008-04-25,Fc receptor binding proteins,,DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/071-787-938-915-904,Granted Patent,no,2,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,,,0,0,,,,ACTIVE
28,CA,C,CA 2722082 C,176-207-678-110-256,2021-11-09,2021,CA 2722082 A,2009-04-24,US 4815208 P;;US 4850008 P;;US 2009/0002536 W,2008-04-25,FC RECEPTOR BINDING PROTEINS,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",BIOGEN IDEC HEMOPHILIA INC;;DYAX CORP,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/176-207-678-110-256,Granted Patent,no,0,0,69,71,190,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61P37/00,,0,0,,,,ACTIVE
29,CN,A,CN 102149729 A,040-067-190-847-015,2011-08-10,2011,CN 200980124409 A,2009-04-24,US 2009/0002536 W;;US 4815208 P;;US 4850008 P,2008-04-25,Antibodies against FcRn and use thereof,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;BIOGEN IDEC HEMOPHILIA INC,CHRISTOPHER TENHOOR;;ARUMUGAM MURUGANANDAM;;CHARLES LADNER ROBERT;;CLIVE WOOD;;BITONTI ALAN J;;JAMES STATTEL;;KEVIN MCDONNELL;;LIMING LIU;;JENNIFER DUMONT;;AARON SATO,,https://lens.org/040-067-190-847-015,Patent Application,no,3,25,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61P37/00,,1,1,046-418-619-195-508,10.4049/jimmunol.178.8.5390;;17404325,"LIU LIMING ET AL: ""Amelioration of Experimental Autoimmune Myasthenia Gravis in Rats by Neonatal FcR Blockade"", 《THE JOURNAL OF IMMUNOLOGY》",ACTIVE
30,KR,A,KR 20110044729 A,172-106-835-997-156,2011-04-29,2011,KR 20107026415 A,2009-04-24,US 4815208 P;;US 4850008 P,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF,,DYAX CORP;;BIOGEN IDEC HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/172-106-835-997-156,Patent Application,no,4,3,69,71,36,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61K39/395;;A61P37/00,,0,0,,,,ACTIVE
31,CN,B,CN 102149729 B,053-064-980-115-730,2014-08-20,2014,CN 200980124409 A,2009-04-24,US 2009/0002536 W;;US 4815208 P;;US 4850008 P,2008-04-25,Antibodies against FcRn and use thereof,,DYAX CORP;;BIOGEN IDEC HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/053-064-980-115-730,Granted Patent,no,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61P37/00,,0,0,,,,ACTIVE
32,BR,A2,BR PI0910622 A2,145-237-532-294-358,2020-03-10,2020,BR PI0910622 A,2009-04-24,US 2009/0002536 W;;US 4815208 P;;US 4850008 P,2008-04-25,anticorpos contra fcrn e usos dos mesmos,"anticorpos contra fcrn e usos dos mesmos esta divulgação fornece, entre outras coisas, proteínas que se ligam a fcrn, por exemplo, imunoglobulinas, que inibem fcrn com alta afinidade e seletividade. as proteínas que se ligam a fcrn podem ser usadas para tratar uma variedade de distúrbios, incluindo distúrbios autoimunes.",BIOGEN IDEC HEMOPHILIA INC;;DYAX CORP,AARON SATO;;ALAN J BITONTI;;ARUMUGAM MURUGANANDAM;;CHRISTOPHER TENHOOR;;CLIVE WOOD;;JAMES STATTEL;;JENNIFER DUMONT;;KEVIN MCDONNELL;;LIMING LIU;;ROBERT CHARLES LADNER,BIOVERATIV THERAPEUTICS INC. (US) ; TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) (2021-12-14);;DYAX CORP. (US) ; BIOVERATIV THERAPEUTICS INC. (US) (2020-10-13);;DYAX CORP. (US) ; BIOGEN IDEC HEMOPHILIA INC. (US) (2020-07-14),https://lens.org/145-237-532-294-358,Patent Application,no,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61P37/00,,0,0,,,,DISCONTINUED
33,MX,A,MX 2010011679 A,189-369-797-871-633,2011-05-23,2011,MX 2010011679 A,2009-04-24,US 4815208 P;;US 4850008 P;;US 2009/0002536 W,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF.,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP,WOOD CLIVE;;TENHORR CHRISTOPHER;;MARUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/189-369-797-871-633,Patent Application,no,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61P37/00,,0,0,,,,ACTIVE
34,EP,B1,EP 2310415 B1,146-269-592-330-325,2017-10-11,2017,EP 09734929 A,2009-04-24,US 2009/0002536 W;;US 4815208 P;;US 4850008 P,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF,,DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,"DYAX CORPORATION (2016-05-25);;BIOVERATIV THERAPEUTICS INC., WALTHAM, US (2021-10-08);;DYAX CORP., BURLINGTON, US (2018-10-15);;TAKEDA PHARMACEUTICAL COMPANY LIMITED, OSAKA-S, JP (2021-10-08);;BIOVERATIV THERAPEUTICS INC. (2018-08-22);;BIOGEN HEMOPHILIA INC. (2017-11-22);;BIOVERATIV THERAPEUTICS INC.; US (2021-11-05);;DYAX CORP. (2018-08-22)",https://lens.org/146-269-592-330-325,Granted Patent,yes,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;G01N33/68,,2,0,,,"LORIN ROSKOS ET AL: ""Molecular Engineering II: Antibody Affinity"", HANDBOOK OF THERAPEUTIC ANTIBODIES, WILEY-VCH, WEINHEIM, no. Part I, Chapter 7, 30 March 2007 (2007-03-30), XP007912251, ISBN: 978-3-527-31453-9, [retrieved on 20080201];;STEPHAN DUEBEL ED - STEFAN DÜBEL: ""Handbook of Therapeutic Antibodies Chapter 6"", 1 January 2007, HANDBOOK OF THERAPEUTIC ANTIBODIES, WILEY-VCH, WEINHEIM, PAGE(S) 119 - 144, ISBN: 978-3-527-31453-9, XP007913671",ACTIVE
35,SG,A,SG 10201804513W A,180-791-218-385-240,2018-07-30,2018,SG 10201804513W A,2009-04-24,US 4815208 P;;US 4850008 P,2008-04-25,Antibodies Against Fcrn And Use Thereof,"ANTIBODIES AGAINST FCRN AND USE THEREOF This disclosure provides, inter alia, proteins that bind to FcRn, e.g. immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a 5 variety of disorders including autoimmune disorders. Figure 36",DYAX CORP;;BIOVERATIV THERAPEUTICS INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/180-791-218-385-240,Unknown,no,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,,,0,0,,,,PENDING
36,WO,A3,WO 2009/131702 A3,055-020-876-922-75X,2010-02-18,2010,US 2009/0002536 W,2009-04-24,US 4815208 P;;US 4850008 P,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g. , immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;SYNTONIX PHARMACEUTICALS INC;;TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/055-020-876-922-75X,Search Report,yes,3,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,A61P37/00;;C07K16/28,,5,5,046-418-619-195-508;;030-199-397-665-51X;;004-906-446-973-883;;085-172-902-751-941;;011-483-806-642-730,10.4049/jimmunol.178.8.5390;;17404325;;15682382;;10.1002/jps.20297;;pmc1280965;;10.1172/jci24394;;16284651;;10.1172/jci200418838;;15124024;;pmc398424;;10.1172/jci18838;;10.1038/nri2155;;17703228,"LIU LIMING ET AL: ""Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade"", JOURNAL OF IMMUNOLOGY, vol. 178, no. 8, April 2007 (2007-04-01), pages 5390 - 5398, XP009124948, ISSN: 0022-1767;;GETMAN KATE E ET AL: ""Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions"", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 94, no. 4, 1 April 2005 (2005-04-01), pages 718 - 729, XP002417287, ISSN: 0022-3549;;LI NING ET AL: ""Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases"", JOURNAL OF CLINICAL INVESTIGATION, vol. 115, no. 12, December 2005 (2005-12-01), pages 3440 - 3450, XP009124853, ISSN: 0021-9738;;AKILESH SHREERAM ET AL: ""The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease"", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 113, no. 9, 1 May 2004 (2004-05-01), pages 1328 - 1333, XP002417288, ISSN: 0021-9738;;ROOPENIAN DERRY C ET AL: ""FcRn: the neonatal Fc receptor comes of age"", NATURE REVIEWS. IMMUNOLOGY, XX, XX, vol. 7, no. 9, 1 September 2007 (2007-09-01), pages 715 - 725, XP002510057, ISSN: 1474-1733",PENDING
37,TW,A,TW 201630626 A,069-411-676-663-606,2016-09-01,2016,TW 105116324 A,2009-04-24,US 4815208 P;;US 4850008 P,2008-04-25,FC receptor binding proteins,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/069-411-676-663-606,Patent of Addition,no,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,A61K39/395;;A61P37/00;;C12N15/13,,0,0,,,,ACTIVE
38,CA,A1,CA 2722082 A1,103-541-025-192-739,2009-10-29,2009,CA 2722082 A,2009-04-24,US 4815208 P;;US 4850008 P;;US 2009/0002536 W,2008-04-25,FC RECEPTOR BINDING PROTEINS,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",BIOGEN IDEC HEMOPHILIA INC;;DYAX CORP,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/103-541-025-192-739,Patent Application,no,0,0,69,71,190,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61P37/00,,0,0,,,,ACTIVE
39,WO,A9,WO 2009/131702 A9,006-067-427-676-507,2010-09-23,2010,US 2009/0002536 W,2009-04-24,US 4815208 P;;US 4850008 P,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g. , immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;SYNTONIX PHARMACEUTICALS INC;;TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/006-067-427-676-507,Search Report,yes,0,1,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,A61P37/00;;C07K16/28,,0,0,,,,PENDING
40,AU,A1,AU 2015/200004 A1,113-769-261-833-722,2015-01-29,2015,AU 2015/200004 A,2015-01-02,AU 2015/200004 A;;AU 2009/238605 A;;US 4850008 P;;US 4815208 P,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoinmune disorders. See Fig. 36. WO 2009/131702 PCT/US2009/002536 - (a, z) ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS - (a, z) GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKK - (f) ----------------------------------------------- - (a, z) VEIPKS...T HTPPCAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVV - (a, z) D - (a, z) LN G KEYKCKVSNiKALPAVI FKITI SKAKGQPREPQVYTLPPSPREPQVYT - (a,z) LPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD - (f)------E-M--------------------------------------- - (a,z) SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* - ----------------------------------- ~---~~~~ (a, z) (SEQ ID NO: 115) (f) (SEQ ID NO: 116) SUBSTITUTE SHEET (RULE 26)",DYAX CORP;;BIOGEN IDEC HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,BIOVERATIV THERAPEUTICS INC. (2022-03-17);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2022-03-17);;DYAX CORP. (2022-03-17),https://lens.org/113-769-261-833-722,Patent Application,no,0,1,2,71,0,,C07K16/28;;A61P37/00,,0,0,,,,ACTIVE
41,AU,A1,AU 2009/238605 A1,168-255-890-617-560,2009-10-29,2009,AU 2009/238605 A,2009-04-24,US 4850008 P;;US 4815208 P;;US 2009/0002536 W,2008-04-25,Antibodies against FcRn and use thereof,,DYAX CORP;;BIOGEN IDEC HEMOPHILIA INC,LADNER ROBERT CHARLES;;WOOD CLIVE;;LIU LIMING;;DUMONT JENNIFER;;MURUGANANDAM ARUMUGAM;;BITONTI ALAN J;;MCDONNELL KEVIN;;SATO AARON;;STATTEL JAMES;;TENHOOR CHRISTOPHER,,https://lens.org/168-255-890-617-560,Patent Application,no,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61P37/00,,0,0,,,,ACTIVE
42,AU,B2,AU 2009/238605 B2,168-592-961-718-885,2014-11-06,2014,AU 2009/238605 A,2009-04-24,US 4850008 P;;US 4815208 P;;US 2009/0002536 W,2008-04-25,Antibodies against FcRn and use thereof,"This disclosure provides, inter alia, proteins that bind to FcRn,",BIOGEN IDEC HEMOPHILIA INC;;DYAX CORP,MCDONNELL KEVIN;;BITONTI ALAN J;;LADNER ROBERT CHARLES;;SATO AARON;;LIU LIMING;;TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;STATTEL JAMES;;DUMONT JENNIFER;;WOOD CLIVE,,https://lens.org/168-592-961-718-885,Granted Patent,no,3,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61P37/00,,0,0,,,,ACTIVE
43,AU,B2,AU 2015/200004 B2,169-468-375-559-488,2017-02-16,2017,AU 2015/200004 A,2015-01-02,AU 2015/200004 A;;AU 2009/238605 A;;US 4850008 P;;US 4815208 P,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoinmune disorders. See Fig. 36. WO 2009/131702 PCT/US2009/002536 - (a, z) ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS - (a, z) GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKK - (f) ----------------------------------------------- - (a, z) VEIPKS...T HTPPCAPELLGGPSVFLFPPKPKDTLMISRT PEVTCVVV - (a, z) D - (a, z) LN G KEYKCKVSNiKALPAVI FKITI SKAKGQPREPQVYTLPPSPREPQVYT - (a,z) LPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD - (f)------E-M--------------------------------------- - (a,z) SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* - ----------------------------------- ~---~~~~ (a, z) (SEQ ID NO: 115) (f) (SEQ ID NO: 116) SUBSTITUTE SHEET (RULE 26)",BIOVERATIV THERAPEUTICS INC;;TAKEDA PHARMACEUTICALS CO,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,BIOVERATIV THERAPEUTICS INC. (2022-03-17);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2022-03-17);;DYAX CORP. (2022-03-17),https://lens.org/169-468-375-559-488,Granted Patent,no,3,0,2,71,0,,C07K16/28;;A61P37/00,,0,0,,,,ACTIVE
44,HK,A1,HK 1160868 A1,020-155-861-772-742,2012-08-17,2012,HK 12101148 A,2012-02-07,US 2009/0002536 W;;US 4815208 P;;US 4850008 P,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF FCRN,,DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/020-155-861-772-742,Patent Application,no,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K/;;A61P/,,0,0,,,,PENDING
45,HK,A1,HK 1207089 A1,076-113-273-795-303,2016-01-22,2016,HK 15107570 A,2015-08-06,US 4815208 P;;US 4850008 P,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF FCRN,,DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/076-113-273-795-303,Patent Application,no,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K/;;A61K/;;A61P/;;G01N/,,0,0,,,,PENDING
46,US,A1,US 2013/0045218 A1,010-061-613-557-197,2013-02-21,2013,US 201213584221 A,2012-08-13,US 201213584221 A;;US 42952909 A;;US 4815208 P;;US 4850008 P,2008-04-25,FC RECEPTOR BINDING PROTEINS,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",SYNTONIX PHARMACEUTICALS INC;;DYAX CORP;;TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON;;VISWANATHAN MALINI,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON;;VISWANATHAN MALINI,SYNTONIX PHARMACEUTICALS INC (2009-06-30);;DYAX CORP (2009-06-19),https://lens.org/010-061-613-557-197,Patent Application,yes,0,8,69,71,190,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;A61K39/395;;A61P1/00;;A61P1/04;;A61P3/10;;A61P19/02;;A61P21/04;;A61P25/00;;A61P37/00;;G01N33/566,424/173.1;;530/389.6;;435/7.21,0,0,,,,DISCONTINUED
47,US,A1,US 2013/0078262 A1,150-352-081-676-983,2013-03-28,2013,US 201213617498 A,2012-09-14,US 201213617498 A;;US 42952909 A;;US 4815208 P;;US 4850008 P,2008-04-25,FC RECEPTOR BINDING PROTEINS,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON;;VISWANATHAN MALINI;;DYAX CORP,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON;;VISWANATHAN MALINI,BIOGEN HEMOPHILIA INC (2009-06-30);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021-02-26);;DYAX CORP (2012-09-17),https://lens.org/150-352-081-676-983,Patent Application,yes,1,5,69,71,190,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28;;G01N33/68,424/173.1;;435/7.92;;435/7.21,0,0,,,,ACTIVE
48,ZA,B,ZA 201007873 B,050-879-180-510-888,2012-02-29,2012,ZA 201007873 A,2010-11-03,US 4815208 P;;US 4850008 P;;US 2009/0002536 W,2008-04-25,ANTIBODIES AGAINST FCRN AND USE THEREOF,,DYAX CORP;;BIOGEN IDEC HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE R;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN A;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON,,https://lens.org/050-879-180-510-888,Granted Patent,no,0,0,69,71,0,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,A61P/;;C07K/,,0,0,,,,ACTIVE
49,US,B2,US 9260520 B2,094-295-235-640-311,2016-02-16,2016,US 201414168839 A,2014-01-30,US 201414168839 A;;US 201213617498 A;;US 42952909 A;;US 4815208 P;;US 4850008 P,2008-04-25,Antibodies to FeRn and uses thereof,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;MCGIVNEY JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON K;;VISWANATHAN MALINI,DYAX CORPORATION (2009-06-19);;BIOGEN HEMOPHILIA INC (2009-06-30);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021-02-26),https://lens.org/094-295-235-640-311,Granted Patent,yes,64,11,69,71,240,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,A61K39/00;;C07K16/28;;G01N33/579;;G01N33/68,,91,71,046-418-619-195-508;;030-199-397-665-51X;;004-906-446-973-883;;085-172-902-751-941;;011-483-806-642-730;;013-592-699-599-09X;;027-477-313-726-928;;095-334-545-560-259;;014-113-432-888-031;;045-942-104-775-903;;051-707-000-800-833;;031-100-076-670-370;;001-779-867-387-972;;013-142-717-038-23X;;006-553-734-546-212;;068-238-957-669-243;;105-316-874-895-908;;033-368-627-556-233;;053-851-713-620-401;;029-611-134-469-353;;099-539-944-702-597;;036-929-348-767-907;;025-426-299-802-257;;000-202-910-533-267;;038-256-556-798-926;;000-782-271-097-14X;;120-214-453-828-332;;054-019-549-143-703;;010-488-381-022-259;;004-863-960-524-08X;;037-479-681-932-129;;041-909-244-299-232;;073-188-128-290-445;;039-262-924-716-099;;119-013-590-539-100;;025-395-146-381-464;;085-277-440-303-853;;038-308-787-457-936;;006-528-517-743-856;;047-865-259-862-039;;005-119-615-003-591;;007-364-858-655-289;;066-841-655-291-162;;063-830-914-171-200;;028-862-168-091-90X;;056-942-841-068-650;;030-034-081-656-451;;039-508-259-975-855;;034-331-211-704-877;;049-134-753-209-354;;048-188-266-680-461;;001-644-035-906-196;;035-803-984-874-05X;;008-778-244-900-75X;;000-092-434-393-958;;023-676-781-371-861;;002-264-966-090-625;;033-797-614-829-293;;013-181-635-285-001;;019-779-601-634-917;;116-821-682-892-530;;136-081-470-295-245;;002-237-818-610-496;;009-817-530-258-10X;;085-812-916-734-336;;029-694-380-116-357;;087-617-084-673-049;;103-477-074-900-777;;003-452-898-892-099;;053-356-650-362-67X;;014-865-054-842-811,10.4049/jimmunol.178.8.5390;;17404325;;15682382;;10.1002/jps.20297;;pmc1280965;;10.1172/jci24394;;16284651;;10.1172/jci200418838;;15124024;;pmc398424;;10.1172/jci18838;;10.1038/nri2155;;17703228;;10.1002/9783527619740.ch7;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1006/jmbi.1996.0548;;8876650;;12218124;;10.4049/jimmunol.169.6.3076;;12850000;;10.1016/s0006-291x(03)01131-8;;12079396;;10.1016/s0022-2836(02)00264-4;;16989900;;10.1016/j.molimm.2006.08.001;;10.1006/jmbi.1999.3192;;10543973;;10556035;;10.1006/jmbi.1999.3141;;8424945;;10.1021/bi00055a024;;10556249;;10.1093/protein/12.10.879;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.1016/s0161-5890(98)00095-9;;10199394;;10586066;;10.4049/jimmunol.163.12.6694;;7516563;;10.1016/s0923-2494(94)80039-1;;10.1056/nejm199901213400311;;9895405;;10.2210/pdb1frt/pdb;;10.1038/372379a0;;7969498;;10.1046/j.1365-2567.1997.00326.x;;pmc1363983;;9370926;;9048207;;10.1007/bf02786322;;8643606;;pmc39277;;10.1073/pnas.93.11.5512;;10.1152/ajprenal.0164.2001;;11788451;;8871627;;10.4049/jimmunol.157.8.3317;;12646614;;10.4049/jimmunol.170.7.3528;;14699147;;10.1074/jbc.c300470200;;19188571;;10.1212/01.wnl.0000341766.59028.9d;;pmc2677532;;15517871;;12391234;;10.4049/jimmunol.169.9.5171;;10373423;;10.1074/jbc.274.26.18218;;10.1016/0076-6879(86)21078-2;;3724495;;10.1038/79494;;10973222;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1038/ng0594-13;;8075633;;10.1042/bj0890114;;14097352;;pmc1202279;;10.1016/s0076-6879(00)28409-7;;11075357;;11101809;;10.1038/82407;;10.1016/0022-2836(92)90639-2;;1507232;;10.1002/jps.2600660104;;833720;;10.1126/science.1494-b;;10.1126/science.242.4885.1494-b;;11160276;;10.4049/jimmunol.166.4.2228;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;2674208;;10.1002/j.1552-4604.1989.tb03403.x;;9570567;;7779254;;10.1016/0167-5699(95)80166-9;;10.1038/352624a0;;1907718;;10.1016/0022-2836(87)90412-8;;3681981;;2315699;;10.1126/science.2315699;;20217455;;10.1007/s00018-010-0318-6;;4185494;;10.1042/bj1130299;;pmc1184636;;10.1016/0019-2791(71)90484-8;;5170158;;6655236;;10.1016/0022-1759(83)90311-3;;10.1126/science.3929380;;3929380;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;2531466;;10.1126/science.2531466;;10.1073/pnas.87.6.2264;;2315319;;pmc53667;;pmc46825;;8390686;;10.1073/pnas.90.12.5873;;7522328;;10.1073/pnas.91.19.9022;;pmc44739;;8790200;;9700502;;10.1111/j.1600-065x.1998.tb01188.x;;9661810;;10.1016/s1380-2933(98)00007-4;;10328771;;10.1006/abio.1999.4063;;10.1016/s0167-5699(00)01667-4;;10916139;;10976071;;10.1126/science.289.5485.1760;;10.1016/s0022-1759(00)00290-8;;11292488;;10.1080/00365520310000654;;12678333;;6847134;;10.1002/ana.410130302;;10.1038/194495a0;;14450081,"Nixon et al. (Frontiers in Immunology 6 (article 176):1-13 (Apr. 23, 2015)).;;Liu et al: ""Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade,"" Journal of Immunology, 178(8), 5390-5398, Apr. 2007.;;Getman et al: ""Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions,"" Journal of Pharmaceutical Sciences, American Pharmaceutical Association, Washington, US, 94(4), 718-729, Apr. 1, 2005.;;Li et al: ""Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases,"" Journal of Clinical Investigation, 115(12), 3440-3450, Dec. 2005.;;Akilesh et al: ""The MHC class I-like Fc receptor promotes humorally mediated autoimmune.disease,"" Journal of Clinical Investigation, American Society for Clinical Investigation, US, 113(9), 1328-1333, May 1 , 2004.;;Roopenian et al: ""FcRn: the neonatal Fc receptor comes of age,"" Nature Reviews Immunology, 7(9), 715-725, Sep. 1, 2007.;;Roskos et al: ""Molecular Engineering II: Antibody Affinity,"" Handbook of Therapeutic Antibodies, 145-169, 2007.;;Rudikoff et al: Single amino acid substitution altering antigen-binding specificity, Proc Natl Acad Sci USA, 79, 1979-1983, Mar. 1982.;;MacCallum et al: ""Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,"" J. Mol. Biol., 262, 732-745, 1996.;;De Pascalis et al: ""Grafting of 'Abbreviated' Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,"" The Journal of Immunology, 169, 3076-3084, 2002.;;Casset et al: ""A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,"" Biochemical and Biophysical Research Communications, 307, 198-205, 2003.;;Vajdos et al: ""Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,"" J. Mol. Biol., 320, 415-428, 2002.;;Holm et al: ""Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1,"" Molecular Immunology, 44, 1075-1084, 2007.;;Chen et al: ""Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,"" J. Mol. Biol., 293, 865-881, 1999.;;Wu et al: ""Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues,"" J. Mol. Biol., 294, 151-162, 1999.;;Brummell et al: ""Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues,"" Biochemistry, 32(4), 1180-1187, 1993.;;Kobayashi et al: ""Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidine photoproduct binding by a high-affinity antibody,"" Protein Engineering, 12(10), 879-884, 1999.;;Burks et al: ""In vitro scanning saturation mutagenesis of an antibody binding pocket,"" Proc. Natl. Acad. Sci. USA, 94, 412-417, 1997.;;Jang et al: ""The structural basis for DNA binding by an anti-DNA autoantibody,"" Molecular Immunology, 35, 1207-1217, 1998.;;Brorson et al: ""Mutational Analysis of Avidity and Fine Specificity of Anti-Levan Antibodies,"" Journal of Immunology, 163, 6694-6701, 1999.;;Colman: ""Effects of amino acid sequence changes on antibody-antigen interactions,"" Research in Immunol., 145, 33-36, 1994.;;Yu et al: ""Mechanism of Intravenous Immune Globulin Therapy in Antibody-Mediatged Autoimmune Diseases,"" The New England Journal of Medicine, Clinical Implications of Basic Research, 340(3), 227-228, 1999.;;Burmeister et al: ""Crystal structure of the complex of rat neonatal Fc receptor with Fc,"" Nature, 372, 379-383, Nov. 24, 1994.;;Israel et al: ""Expression of the neonatal Fe receptor, FcRn, on human intestinal epithelial cells,"" Immunology, 92, 69-74, 1997.;;Junghans et al: ""Finally! The Brambell Receptor (FcRB),"" Immunologic Research, 16(1), 29-57, 1997.;;Junghans et al: ""The protection receptor for IgG catabolism is the B2-microglobulin-containing neonatal intestinal transport receptor"" Proc. Natl. Acad. Sci. USA, 93, 5512-5516, May 1996.;;Kobayashi et al: ""FcRn-mediated transcytosis of Immunoglobulin G in human renal proximal tubular epithelial cells,"" Am J Physiol Renal Physiol, 282, F358-F365, 2002.;;Leach et al: ""Isolation from Human Placenta of the IgG Transporter, FcRn, and Localization to the Syncytiotrophoblast,"" The American Journal of Immunology, 157, 3317-3322, 1996.;;Roopenian et al: ""The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs,"" The Journal of Immunology, 170, 3528-3533, 2003.;;Hinton et al: ""Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates,"" The Journal of Biological Chemistry, 279(8), 6213-6216, 2004.;;Khatri et al: ""Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function,"" Neurology, 72, 402-409, Feb. 3, 2009.;;Onuma et al: ""Generation of a Humanized Monoclonal Antibody Against Human Parathyroid Hormone-related Protein and its Efficacy Against Humoral Hypercalcemia of Malignancy,"" Anticancer Research, 24, 2665-2673, 2004.;;Dali' Acqua, et al., ""Increasing the Affnity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences"", J. Immunol. 2002: 169:5171-5180.;;De Haard, et al., ""A Large Non-immunized Human Fab Fragment Phage Library That Permits Rapid Isolation and Kinetic Analysis of High Affinity Antibodies"", J. Biol. Chem., 1999, vol. 274: pp. 18218-18230.;;Colcher et al., ""[76] Use of Monoclonal Antibodies as Radiopharmaceuticals for the Localization of Human Carcinoma Xenografts in Athymic Mice"", 1986, Meth. Enzymol., vol. 121: pp. 802-816.;;De Wildt, et al., ""Antibody arrays for high-throughput screening of atibody-antigen interactions"", Nat. Biotechnol., 2000, vol. 18: pp. 989-994.;;Gram, et al., ""In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library"", PNAS USA, 1992, vol. 89, pp. 3576-3580.;;Green, et al., ""Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs"", Nature Genetics, May, 1994, vol. 7, pp. 13-21.;;Greenwood, et al., ""The Preparation of 131I-Labelled Human Growth Hormone of High Specific Radioactivity"", Biochem. J., 1963, vol. 89 pp. 114-123.;;Hanes, et al., ""[24] Selecting and Evolving Functional Proteins in Vitro by Ribosime Display"",(2000). Methods Enzymol., 2000, vol. 328 pp. 404-430.;;Hanes, et al., ""Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display"", Nat. Biotechnol., 2000, vol. 18, pp. 1287-1292.;;Hawkins, et al., ""Selection of Phage Antibodies by Affinity Mimicking Affinity Maturation"", J. Mol. Biol., 1992, vol. 226, pp. 889-896.;;Berge, et al., ""Review Article-Pharmaceutical Salts"", J. Pharm. Sci., Jan. Jan. 1977, vol. 66, pp. 1-19.;;Bird, et al., ""Single-Chain Antigen-Binding Proteins"", Science, Oct. 21, 1988, vol. 242, pp. 423-426.;;Bergthorsdottir, et al. ""Signals that Initiate Somatic Hypermutation of B Cells In Vitro"", J. Immunol., 2001, vol. 166, pp. 2228-2234.;;Altschul et al., ""Gapped BLAST and PST-BLAST: a new generation of protein database search programs"", Nucleic Acids Res., 1997, vol. 25 No. 17, pp. 3389-3402.;;Ranade, ""Drug Delivery Systems, 1, Site-Specific Drug Delivery Using Liposomes as Carriers"", J. Clin. Pharmacol., 1989, vol. 29, pp. 685-694.;;Costagliola, et al., ""Genetic Immunization Against the Human Thyroiditis and Allows Production of Monoclonal Antibodies Recognizing the Native Receptor"", J. Immunology, 1998, vol. 160, pp. 1458-1465.;;Cook, et al., ""The human immunoglobulin VH repertoire"", Immunol. Today, 1995, vol. 16, No. 5, pp. 237-242.;;Clackson, et al., ""Making antibody fragments using phage display libraries"", Nature, Aug. 1991, vol. 352, pp. 624-628.;;Chothia, et al., ""Canonical Structures for the Hypervariable Regions of Immunoglobullins"", J. Mol. Biol., 1987, vol. 196, pp. 901-917.;;Bowie, et al., ""Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions"", Science, vol. 247, pp. 1306-1310.;;Singapore Application No. 2013085204-Search Report mailed Nov. 28, 2014.;;Singapore Application No. 2013085204-Invitation to Respond to Written Opinion mailed Dec. 5, 2014.;;Sesarman, et al., ""The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases"", Cell. Mol. Life Sci., 2010; vol. 67, No. 15, pp. 2533-2550.;;Israel Application No. 208B46-Official Action dated Jul. 31, 2014 (with English translation).;;Chinese Application No. 200980124409.1-First Official Action issued Dec. 11, 2012.;;Japanese Application No. 2011-506301-Notification of Reason for Refusal issued Oct. 24, 2013.;;Japanese Application No. 2011-506301-Decision of Retection issued Oct. 16, 2014.;;Philippines Application No. 1/2010/502415-Substantive Examination Report mailed Jul. 26, 2013.;;Mexican Application No. MX/a/2010/011679-Second Official Letter (Translation only, mailed Apr. 2, 2013).;;PCT Application No. PCT/US2009/002536-International Preliminary Report on Patentability mailed Nov. 4, 2010.;;PCT Application No. PCT/US2009/002536-International Search Report/Written Opinion mailed Dec. 16, 2009.;;Taiwian Application No. 098113830-Search Report issued Jan. 23, 2014.;;U.S. Appl. No. 12/429,529-Office Action issued Sep. 9, 2011.;;Chinese Application No. 201280031902.0-Office Action/Search Report issued Jul. 3, 2014 (English translation of Seach Report only).;;EP Application No. 12793948.6-Extended European Search Report mailed Oct. 17, 2014.;;CN Application No. 201280031902.0-Office Action issued Mar. 24, 2015 (with English translation).;;U.S. Appl. No. 14/122,880-Office Action issued Mar. 23, 2015.;;Chinese Application No. 200980124409.1-Second Office Action issued Jul. 8, 2013 (with English translation).;;Israel Application No. 208846-Office Action issued Jul. 3, 2012 (with English Translation.;;Canadian Application No. 2,277,082-Examination Search Report mailed May 6, 2015.;;Marchalonis, J., ""An Enzymic Method for the /Trace Iodination of Immunoglobulins and other Proteins"", 1969, Biochem. J., 113: 299-305.;;Morrison, et al., ""Use of Lactoperoxidase Catalyzed Iodination in Immunochemical Studies"", 1971, Immunochemistry, vol. 8, 289-297.;;Hnatowich, et al., ""The Preparation of DTPA-Coupled Antibodies Radiolabeled with Metallic Radionuclides: an Improved Method"", 1983, J. Immunol. Methods, vol. 65:147-157.;;Morrison, S.L., ""Transfectomas Provide Novel Chimeric Antibodies"", 1985, Science, vol. 229: 1202-1207.;;Huston, et al., ""Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli"", 1988, Proc. Natl. Acad. Sci. USA, vol. 85: 5879-5883.;;Huse, et al., ""Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda"", Dec. 8, 1989, Science, vol. 246: 1275-1281.;;Karlin and Altschul, ""Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes"", Mar. 1990, Proc. Natl. Acad. Sci. USA, vol. 87, 2264-2268.;;Karlin and Altschul, ""Applications and statistics for multiple high-scoring segments in molecular sequences"", Jun. 1993, Proc. Natl. Acad. Sci. USA, vol. 90: 5873-5877.;;Mattheakis, et al., ""An in vitro polysome display system for identifying ligands from very large peptide libraries"", Sep. 1994, Proc. Natl. Acad. Sci. USA, vol. 91: 9022-9026.;;Meredith, et al., ""Intraperitoneal Radioimmunotherapy of Ovarian Cancer with Lutetium-177-CC49"", 1996, J. Nucl. Med., vol. 37: 1491-1496.;;Jefferis, et al., ""lcg-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation"", 1998, Immunol. Rev., vol. 163: 59-76.;;Hoogenboom, et al., ""Antibody phage display technology and its applications"", 1998, Immunotechnology, vol. 4: 1-20.;;Lueking, et al., ""Protein Microarrays for Gene Expression and Antibody Screening"", 1999, Anal. Biochem., vol. 270: 103-111.;;Hoogenboom, et al., ""Natural and designer binding sites made by phage display technology"", 2000, Immunol. Today, vol. 2, No. 8: 371-378.;;MacBeath, et al., ""Printing Proteins as Microarrays for High-Throughput Function Determination"", Sep. 2000, Science vol. 289: 1760-1763.;;Powers, et al., ""Expression of single-chain Fv-Fc Fusions in Pichia pastoris"", 2001, J. Immunol. Methods, vol. 251: 123-35.;;Jowett et al., ""Defining Relapse of Ulcerative Colitis Using a Sympton-based Activity Index"", 2003, Scan. J. Gastroenterol. 38(2): 164-171.;;Poser, et al., ""New Diagnostic Criteria for Multiple Sclerosis: Guidelines for Research Protocols"", Mar. 1983, Ann. Neurol., vol. 13, No. 3: 227-231.;;Hunter and Greenwood, ""Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity"" May 1962, Nature vol. 194: 495-496.",ACTIVE
50,US,A1,US 2014/0248287 A1,139-087-396-013-807,2014-09-04,2014,US 201414168839 A,2014-01-30,US 201414168839 A;;US 201213617498 A;;US 42952909 A;;US 4815208 P;;US 4850008 P,2008-04-25,FC RECEPTOR BINDING PROTEINS,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",SYNTONIX PHARMACEUTICALS INC;;DYAX CORP,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON K;;VISWANATHAN MALINI,DYAX CORPORATION (2009-06-19);;BIOGEN HEMOPHILIA INC (2009-06-30);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021-02-26),https://lens.org/139-087-396-013-807,Patent Application,yes,1,10,69,71,240,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28,424/172.1,1,0,,,Nixon et al. (Frontiers in Immunology 6 (article 176):1-13 (4/23/15)),ACTIVE
51,US,B2,US 8815246 B2,057-715-127-965-983,2014-08-26,2014,US 201213617498 A,2012-09-14,US 201213617498 A;;US 42952909 A;;US 4815208 P;;US 4850008 P,2008-04-25,Fc receptor binding proteins,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON K;;VISWANATHAN MALINI;;DYAX CORP;;SYNTONIX PHARMACEUTICALS INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;STATTEL JAMES;;MCDONNELL KEVIN;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON K;;VISWANATHAN MALINI,BIOGEN HEMOPHILIA INC (2009-06-30);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021-02-26);;DYAX CORP (2012-09-17),https://lens.org/057-715-127-965-983,Granted Patent,yes,15,11,69,71,190,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,G01N33/68;;C07K16/28,424/173.1,31,31,085-172-902-751-941;;053-851-713-620-401;;006-553-734-546-212;;105-316-874-895-908;;036-929-348-767-907;;045-942-104-775-903;;001-779-867-387-972;;029-611-134-469-353;;041-909-244-299-232;;014-113-432-888-031;;030-199-397-665-51X;;010-488-381-022-259;;031-100-076-670-370;;025-426-299-802-257;;033-368-627-556-233;;038-256-556-798-926;;000-202-910-533-267;;004-863-960-524-08X;;000-782-271-097-14X;;068-238-957-669-243;;120-214-453-828-332;;004-906-446-973-883;;046-418-619-195-508;;095-334-545-560-259;;037-479-681-932-129;;011-483-806-642-730;;054-019-549-143-703;;027-477-313-726-928;;051-707-000-800-833;;013-142-717-038-23X;;099-539-944-702-597,10.1172/jci200418838;;15124024;;pmc398424;;10.1172/jci18838;;10586066;;10.4049/jimmunol.163.12.6694;;8424945;;10.1021/bi00055a024;;pmc19525;;9012796;;10.1073/pnas.94.2.412;;10.2210/pdb1frt/pdb;;10.1038/372379a0;;7969498;;12850000;;10.1016/s0006-291x(03)01131-8;;10.1006/jmbi.1999.3192;;10543973;;7516563;;10.1016/s0923-2494(94)80039-1;;12391234;;10.4049/jimmunol.169.9.5171;;12218124;;10.4049/jimmunol.169.6.3076;;15682382;;10.1002/jps.20297;;14699147;;10.1074/jbc.c300470200;;16989900;;10.1016/j.molimm.2006.08.001;;10.1046/j.1365-2567.1997.00326.x;;pmc1363983;;9370926;;10.1016/s0161-5890(98)00095-9;;10199394;;8643606;;pmc39277;;10.1073/pnas.93.11.5512;;9048207;;10.1007/bf02786322;;19188571;;10.1212/01.wnl.0000341766.59028.9d;;pmc2677532;;10.1152/ajprenal.0164.2001;;11788451;;10556249;;10.1093/protein/12.10.879;;8871627;;10.4049/jimmunol.157.8.3317;;pmc1280965;;10.1172/jci24394;;16284651;;10.4049/jimmunol.178.8.5390;;17404325;;10.1006/jmbi.1996.0548;;8876650;;15517871;;10.1038/nri2155;;17703228;;12646614;;10.4049/jimmunol.170.7.3528;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;12079396;;10.1016/s0022-2836(02)00264-4;;10556035;;10.1006/jmbi.1999.3141;;10.1056/nejm199901213400311;;9895405,"Akilesh et al., The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest. May 2004;113(9):1328-33.;;Brorson et al., Mutational analysis of avidity and fine specificity of anti-levan antibodies. J Immunol. Dec. 15, 1999;163(12):6694-701.;;Brummell et al., Probing the combining site of an anti-carbohydrate antibody by saturation-mutagenesis: role of the heavy-chain CDR3 residues. Biochemistry. Feb. 2, 1999;32(4):1180-7.;;Burks et al., In vitro scanning saturation mutagenesis of an antibody binding pocket. Proc Natl Acad Sci U S A. Jan. 21, 1997;94(2):412-7.;;Burmeister et al., Crystal structure of the complex of rat neonatal Fc receptor with Fc, Nature 372:366 (1994).;;Casset et al., A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem Biophys Res Commun. Jul. 18, 2003;307(1):198-205.;;Chen et al., Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. Nov. 5, 1999;293(4):865-81.;;Colman, Effects of amino acid sequence changes on antibody-antigen interactions. Res Immunol. Jan. 1994;145(1):33-6.;;Dall' Acqua et al., Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol. Nov. 1, 2002;169(9):5171-80.;;De Pascalis et al., Grafting of ""abbreviated"" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. J Immunol. Sep. 15, 2002; 69(6):3076-84.;;Getman et al., Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. J Pharm Sci. Apr. 2005;94(4):718-29.;;Hinton et al., Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem. 2004 Feb. 20, 2004;279(8):6213-6. Epub Dec. 29, 2003.;;Holm et al., Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Mol Immunol. Feb. 2007;44(6):1075-84. Epub Sep. 20, 2006.;;Israel et al., Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells, Immunology 92:69 (1997).;;Jang et al., The structural basis for DNA binding by an anti-DNA autoantibody. Mol Immunol. Dec. 1998;35(18):1207-17.;;Junghans et al., The protection receptor for IgG catabolism is the 62-microglobulincontaining neonatal intestinal transport receptor, Proc. Natl. Acad. Sci. USA 93:5512-5516 (1996).;;Junghans, Finally! The Brambell Receptor (FcRB), Immunologic Research 16(1):29-57 (1997).;;Khatri et al., Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. Feb. 3, 2009;72(5):402-9.;;Kobayashi et al., FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells, Am J Physiol Renal Physiol 282:F358 (2002).;;Kobayashi et al., Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody. Protein Eng. Oct. 1999;12(10):879-84.;;Leach et al., Isolation from Human Placenta of the IgG Transporter, FcRn, and Localization to the Syncytiotrophoblast, J Immunol 157:3317 (1996).;;Li et al., Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases, J Clin Invest 115:3440-3450 (2005).;;Liu et al., Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. J Immunol. Apr. 15, 2007;178(8):5390-8.;;MacCallum et al., Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol. Oct. 11, 1996;262(5):732-45.;;Onuma et al., Generation of a humanized monoclonal antibody against human parathyroid hormone-related protein and its efficacy against humoral hypercalcemia of malignancy. Anticancer Res. Sep.-Oct. 2004;24(5A):2665-73.;;Roopenian et al., FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. Sep. 2007;7(9):715-25. Epub Aug. 17, 2007.;;Roopenian et al., The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostatis, and Fate of IgG-Fc-Coupled Drugs, J. Immunology 170:3528 (2003).;;Rudikoff et al., Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.;;Vajdos et al., Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol. Jul. 5, 2002;320(2):415-28.;;Wu et al., Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. J Mol Biol. Nov. 19, 1999;294(1):151-62.;;Yu et al., Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med. Jan. 21, 1999;340(3):227-8.",ACTIVE
52,US,A1,US 2016/0194397 A1,060-461-227-051-573,2016-07-07,2016,US 201514985614 A,2015-12-31,US 201514985614 A;;US 201414168839 A;;US 201213617498 A;;US 42952909 A;;US 4815208 P;;US 4850008 P,2008-04-25,FC RECEPTOR BINDING PROTEINS,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;MCGIVNEY JAMES M;;MCDONNELL KEVIN A;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON K;;VISWANATHAN MALINI,BIOGEN HEMOPHILIA INC (2009-06-30);;DYAX CORP (2009-06-19),https://lens.org/060-461-227-051-573,Patent Application,yes,0,12,69,71,244,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28,,0,0,,,,DISCONTINUED
53,US,A1,US 2016/0222108 A1,172-254-725-426-015,2016-08-04,2016,US 201514979165 A,2015-12-22,US 201514979165 A;;US 201414168839 A;;US 201213617498 A;;US 42952909 A;;US 4815208 P;;US 4850008 P,2008-04-25,FC RECEPTOR BINDING PROTEINS,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;MCGIVNEY JAMES M;;MCDONNELL KEVIN A;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON K;;VISWANATHAN MALINI,BIOVERATIV THERAPEUTICS INC (2009-06-30);;TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021-02-26);;DYAX CORP (2012-09-17),https://lens.org/172-254-725-426-015,Patent Application,yes,7,4,69,71,244,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28,,4,4,118-091-505-827-907;;037-670-630-418-918;;094-760-916-029-770;;121-338-854-547-698,10.1016/j.sbi.2020.11.008;;33610066;;pmc8177482;;pmc7380193;;32409582;;10.1074/jbc.rev120.010181;;33730590;;10.1016/j.celrep.2021.108856;;34058977;;10.1186/s12864-020-07303-5;;pmc8165135,"Vajda et al., “Progress toward improved understanding of antibody maturation,” Current Opinion in Structural Biology, 67 pp. 226-231 (2021);;Marks et al., “How repertoire data are changing antibody science,” J. Biol. Chem. 295(29) 9823-9837 (2020));;Akbar et al., Cell Reports 34, 108856, Mar. 16, 2021;;Lo et al., “Conformational epitope matching and prediction based on protein surface spiral features,” BMC Genomics volume 22, Article number: 116 (2021)",DISCONTINUED
54,US,A1,US 2016/0222109 A1,149-067-145-973-218,2016-08-04,2016,US 201514982521 A,2015-12-29,US 201514982521 A;;US 201414168839 A;;US 201213617498 A;;US 42952909 A;;US 4815208 P;;US 4850008 P,2008-04-25,FC RECEPTOR BINDING PROTEINS,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;MCGIVNEY JAMES M;;MCDONNELL KEVIN A;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON K;;VISWANATHAN MALINI,BIOGEN HEMOPHILIA INC (2009-06-30);;DYAX CORP (2009-06-19),https://lens.org/149-067-145-973-218,Patent Application,yes,0,4,69,71,244,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28,,0,0,,,,DISCONTINUED
55,US,A1,US 2016/0222110 A1,171-527-089-234-198,2016-08-04,2016,US 201514982649 A,2015-12-29,US 201514982649 A;;US 201414168839 A;;US 201213617498 A;;US 42952909 A;;US 4815208 P;;US 4850008 P,2008-04-25,FC RECEPTOR BINDING PROTEINS,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;MCGIVNEY JAMES M;;MCDONNELL KEVIN A;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON K;;VISWANATHAN MALINI,BIOGEN HEMOPHILIA INC (2009-06-30);;DYAX CORP (2009-06-19),https://lens.org/171-527-089-234-198,Patent Application,yes,0,4,69,71,244,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,A61K49/00;;C07K16/28;;A61K49/16;;A61K51/10;;G01N33/68,,0,0,,,,DISCONTINUED
56,US,A1,US 2016/0222112 A1,199-611-423-549-426,2016-08-04,2016,US 201514984162 A,2015-12-30,US 201514984162 A;;US 201414168839 A;;US 201213617498 A;;US 42952909 A;;US 4815208 P;;US 4850008 P,2008-04-25,FC RECEPTOR BINDING PROTEINS,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;MCGIVNEY JAMES M;;MCDONNELL KEVIN A;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON K;;VISWANATHAN MALINI,BIOGEN HEMOPHILIA INC (2009-06-30);;DYAX CORP (2009-06-19),https://lens.org/199-611-423-549-426,Patent Application,yes,0,7,69,71,244,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28,,0,0,,,,DISCONTINUED
57,US,A1,US 2016/0222111 A1,001-265-111-710-68X,2016-08-04,2016,US 201514984075 A,2015-12-30,US 201514984075 A;;US 201414168839 A;;US 201213617498 A;;US 42952909 A;;US 4815208 P;;US 4850008 P,2008-04-25,FC RECEPTOR BINDING PROTEINS,"This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.",DYAX CORP;;BIOGEN HEMOPHILIA INC,TENHOOR CHRISTOPHER;;MURUGANANDAM ARUMUGAM;;LADNER ROBERT CHARLES;;WOOD CLIVE;;BITONTI ALAN J;;MCGIVNEY JAMES M;;MCDONNELL KEVIN A;;LIU LIMING;;DUMONT JENNIFER;;SATO AARON K;;VISWANATHAN MALINI,BIOGEN HEMOPHILIA INC (2009-06-30);;DYAX CORP (2009-06-19),https://lens.org/001-265-111-710-68X,Patent Application,yes,0,4,69,71,244,A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;A61K39/395;;C07K16/28;;C12N15/09;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/34;;A61P37/00;;C07K16/283;;G01N33/68;;C07K16/28;;C07K2317/33;;C07K2317/76;;C07K2317/92;;C07K2317/55;;A61K49/0058;;A61K49/16;;A61K51/1027;;C07K2317/20;;G01N33/6854;;G01N2333/70535,C07K16/28,,1,0,,,"NCBI Protein sequence database search (""neontal Fc Receptor); pp.1-2; 8/26/16)",DISCONTINUED
